Ozempic Lawsuit [September 2026 Update] | File a Claim Today

A newly filed lawsuit claims Eli Lilly and Novo Nordisk failed to warn diabetic patients about the risk of vision loss associated with their GLP-1 drugs. 

The complaint was filed by the plaintiff in the U.S. District Court for the Eastern District of Pennsylvania on September 1, naming Eli Lilly and Company Inc., Novo Nordisk Inc. and Novo Nordisk A/S as defendants.

The plaintiff was prescribed Mounjaro in May 2023 to treat type 2 diabetes before switching to Ozempic in April 2024. 

By June 2024, vision in his right eye began deteriorating and became increasingly blurry. On July 1, 2024, he woke up unable to see out of that eye. 

Multiple specialists later confirmed the vision loss was permanent.

The complaint alleges reports linking GLP-1 medications to vision problems date back to at least 2012. 

It claims researchers have raised concerns that these complications may have been underreported during clinical trials. 

The plaintiff alleges the manufacturers continued promoting the drugs without updating warning labels, while concealing internal data on the risk.

The case is based on claims of inadequate warning and breach of express warranty. 

The plaintiff seeks compensatory damages covering pain and suffering and medical expenses.

The complaint was filed directly in the Eastern District of Pennsylvania, where federal Ozempic and Mounjaro vision loss lawsuits are coordinated in MDL No. 3163 before Judge Karen Marston. 

The litigation was established in December 2025 and is currently in early discovery, with proceedings focused on whether GLP-1 drugs can cause NAION and whether certain claims are preempted by federal law.

The GLP-1 NAION litigation now has a firm schedule for the coming arguments over general causation, preemption and failure to warn claims.

Judge Marston’s case management order sets deadlines carrying the case through expert discovery and summary judgment briefing over the next year:

• Plaintiffs must submit the proposed Plaintiff Fact Sheet by September 25th.
• The master complaint, covering allegations common to all claims, is due October 28.
• Fact discovery against Eli Lilly is due December 18, 2026, followed by discovery against Novo Nordisk on February 26th, 2027.
• Plaintiffs’ general causation expert reports are due March 26th, 2027.
• Defense expert reports follow April 23, with expert depositions completed by June 4th.
• Expert challenges and summary judgment motions are due July 2nd, 2027.
• Opposition briefs are due August 13, with replies due August 31st.

The court’s rulings on these motions will address issues affecting nearly every NAION claim in the litigation, including whether the underlying science is strong enough to establish that GLP-1 drugs cause NAION.

An Indiana woman has sued Novo Nordisk, alleging neither she nor her doctor were ever warned that Ozempic could cause vision loss.

She filed the complaint August 27 in the U.S. District Court for the Eastern District of Pennsylvania.

She was first prescribed Ozempic in May 2024 to manage her Type 2 diabetes. She woke up one morning to discover she’d lost a significant portion of her vision.

Doctors have told her the loss is likely permanent.

The suit alleges Novo Nordisk knew or should have known semaglutide could cause NAION, a condition where reduced blood flow damages the optic nerve.

A 2024 study found diabetic patients on the drug were more than four times as likely to develop NAION, while those using it for weight loss were more than seven times as likely.

The suit alleges the company downplayed the risk to protect sales rather than update warning labels.

It brings claims including failure to warn, design defect, and negligent misrepresentation, seeking compensatory and punitive damages.

The case will be coordinated with hundreds of similar NAION claims before a federal judge in the Eastern District of Pennsylvania, who is separately overseeing a larger group of GLP-1 gastroparesis lawsuits proceeding on a different track.

A growing wave of lawsuits alleges GLP-1 medications, including Ozempic, Wegovy, Mounjaro, and Zepbound, may cause a rare and permanent form of vision loss. 

The litigation is centralized before a federal judge in Philadelphia and currently includes more than 130 cases alleging the drugs caused non-arteritic anterior ischemic optic neuropathy, or NAION, sometimes called an “eye stroke.” 

The condition occurs when blood flow to the optic nerve is disrupted, resulting in sudden, irreversible vision loss.

A 2024 study published in JAMA Ophthalmology found diabetic patients prescribed GLP-1 medications were more than four times as likely to be diagnosed with NAION, while overweight patients on the drugs were more than seven times as likely. Plaintiffs allege they were never warned about this risk. 

One attorney representing plaintiffs described clients as young as 33 losing vision suddenly and permanently, including one who lost sight in both eyes. 

Novo Nordisk has pointed to its own 96,000-patient study finding no increased risk, and Eli Lilly says its testing found no causal relationship between GLP-1 drugs and NAION.

The NAION litigation is separate from other GLP-1 cases alleging gastrointestinal injuries and pulmonary embolisms, though both are consolidated in the same Eastern District of Pennsylvania court under related MDL numbers. 

As the litigation moves forward, the central legal question will be whether the drugs contributed to patients’ NAION diagnoses and whether manufacturers adequately warned consumers and doctors about the risk.

The GLP-1 MDL added 94 cases between August and September, increasing from 3,928 to 4,022.

The litigation has now surpassed 4,000 pending cases as the court continues addressing expert evidence on whether GLP-1 medications can cause gastroparesis and other serious gastrointestinal injuries.

The upcoming causation rulings remain a critical step for determining which Ozempic and other GLP-1 claims can move toward bellwether trials.

If you or a loved one suffered from gastrointestinal issues or vision loss after taking GLP-1 medications, you may be eligible to file a lawsuit against the drug makers.

Contact the GLP-1 attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file a lawsuit instantly.

The Ozempic GLP-1 MDL added 80 cases between July and August, increasing from 3,848 to 3,928.

The litigation continued to advance as the court considered key Daubert motions challenging expert testimony on whether GLP-1 medications can cause gastroparesis and other gastrointestinal injuries. 

Those rulings are expected to determine which scientific evidence reaches future bellwether juries.

With nearly 4,000 pending lawsuits, the Ozempic MDL remains one of the fastest-growing pharmaceutical litigations in federal court.

If you or a loved one suffered from gastrointestinal issues or vision loss after taking GLP-1 medications, you may be eligible to file a lawsuit against the drug makers.

Contact the GLP-1 attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file a lawsuit instantly.

Judge Karen Marston issued a July 2 case management order directing early discovery in the Ozempic and Wegovy NAION litigation to focus first on “cross-cutting issues”: whether plaintiffs can establish general causation between GLP-1 drugs and vision loss, and whether federal law preempts failure-to-warn claims. 

The order resolves a dispute between the parties, with Marston siding with defendants over plaintiffs, who wanted to move directly into full discovery and begin preparing bellwether cases.

Defendants have proposed completing fact discovery by October 2026, expert discovery by year-end, and full briefing on motions by the first quarter of 2027. 

Marston rejected plaintiffs’ argument that this sequencing would slow the litigation, noting that marketing discovery and plaintiffs’ fact sheets will proceed concurrently so bellwether selection can begin quickly if the case isn’t resolved on the early motions. 

The parties must submit a proposed scheduling order by July 13, 2026. More than 130 GLP-1 vision loss lawsuits are now consolidated before Marston in the Eastern District of Pennsylvania. 

Plaintiffs had also raised concerns that the early discovery process could put the NAION litigation out of sync with Marston’s separate GLP-1 stomach paralysis MDL, which involves thousands of cases and is proceeding toward its own independent bellwether process.

The Ozempic GLP-1 MDL added 85 cases between June and July, increasing from 3,763 to 3,848.

The litigation continued to expand as the parties moved into the next phase of expert challenges, with the court considering evidence on whether GLP-1 medications can cause gastroparesis and other serious gastrointestinal injuries.

Summary judgment briefing also continued following the close of Daubert motions.

The court’s upcoming rulings on expert testimony are expected to shape which claims proceed toward bellwether trials.

If you or a loved one suffered from gastrointestinal issues or vision loss after taking GLP-1 medications, you may be eligible to file a lawsuit against the drug makers.

Contact the GLP-1 attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file a lawsuit instantly.

A Massachusetts man has filed a product liability lawsuit against Novo Nordisk, alleging that Wegovy caused him to develop non-arteritic anterior ischemic optic neuropathy (NAION), resulting in permanent blindness in his left eye.

The complaint was filed in the U.S. District Court for the Eastern District of Pennsylvania.

It alleges that Novo Nordisk failed to adequately warn consumers and healthcare providers about the risk of severe vision injuries associated with semaglutide-based medications.

According to the lawsuit, the plaintiff used Wegovy as prescribed before experiencing sudden vision loss.

He was later diagnosed with NAION, a condition involving reduced blood flow to the optic nerve that can cause irreversible blindness.

The filing comes amid increasing scrutiny of potential vision-related side effects linked to GLP-1 receptor agonists. These medications include Wegovy and Ozempic.

Recent studies have examined whether semaglutide use may be associated with a higher risk of developing NAION.

The research has prompted additional claims from individuals who experienced similar injuries.

The case adds to the growing body of GLP-1 litigation. Plaintiffs throughout the litigation allege that manufacturers failed to provide adequate warnings about serious health risks associated with the medications.

Vision loss claims are emerging as a new area of focus within the broader GLP-1 litigation.

The lawsuits already include allegations involving gastroparesis, bowel obstruction, ileus, and other gastrointestinal injuries.

As additional lawsuits are filed, courts will likely examine whether manufacturers had sufficient evidence of potential vision risks.

The litigation is also expected to focus on whether existing warning labels adequately informed patients and physicians.

New research examining a potential link between semaglutide medications and vision loss is drawing increased attention as lawsuits involving Ozempic and Wegovy continue to grow nationwide.

Recent studies have reported a higher incidence of non arteritic anterior ischemic optic neuropathy (NAION), a rare condition that can cause sudden and permanent vision loss, among some users of semaglutide based drugs.

Plaintiffs in the litigation allege that manufacturers failed to adequately warn patients and healthcare providers about the potential risk of NAION and other serious vision related injuries.

Federal courts have already centralized GLP 1 vision loss claims in a multidistrict litigation proceeding in the Eastern District of Pennsylvania to coordinate pretrial proceedings.

The research fueling these claims includes studies that found semaglutide users may face a significantly higher risk of developing NAION compared to patients using other medications.

However, researchers and regulators continue to evaluate whether the observed association reflects a causal relationship.

The litigation remains in its early stages, with plaintiffs seeking damages for alleged vision injuries and manufacturers expected to challenge claims regarding causation and warning adequacy.

The Ozempic GLP-1 MDL added 127 cases between May and June, increasing from 3,636 to 3,763.

The growth follows a significant May ruling in which the court allowed key expert testimony regarding gastroparesis and other gastrointestinal injuries to proceed, preserving important evidence for plaintiffs as the litigation moves forward.

The decision keeps several core injury claims on track and marks an important step toward future bellwether trial preparations.

If you or a loved one suffered from gastrointestinal issues or vision loss after taking GLP-1 medications, you may be eligible to file a lawsuit against the drug makers.

Contact the GLP-1 attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file a lawsuit instantly.

May 22nd, 2026: Judge Allow

A Pennsylvania federal judge denied Eli Lilly’s attempt to restrict testimony from former FDA Commissioner Dr. David Kessler in the multidistrict litigation involving GLP-1 weight loss and diabetes drugs, ruling that the challenged opinions were sufficiently disclosed in his expert report.

The dispute focused on whether Kessler intended to offer new opinions beyond those outlined in his reports concerning GLP-1 receptor agonists, including drugs such as Mounjaro, Trulicity, Ozempic, Wegovy, and Zepbound.

Eli Lilly argued that deposition testimony and post-report notes suggested plaintiffs planned to introduce previously undisclosed opinions related to gastrointestinal injuries and warning adequacy.

The court ultimately found that the opinions plaintiffs intended to rely on were either directly included in Kessler’s reports or represented reasonable elaborations of disclosed opinions.

The ruling allows plaintiffs to continue relying on expert testimony concerning delayed gastric emptying, gastrointestinal complications, adequacy of warning labels, and alleged deficiencies in safety analyses submitted to the FDA.

The decision is significant for the broader GLP-1 multidistrict litigation, where plaintiffs allege drug manufacturers failed to adequately warn consumers about risks including gastroparesis, bowel obstruction, ileus, and other injuries while aggressively marketing the medications for weight loss.

Expert testimony on causation and labeling remains central to the litigation as the parties prepare for future dispositive motions and bellwether proceedings.

A new Ozempic lawsuit filed in federal court alleges that the blockbuster diabetes and weight loss drug caused a Massachusetts man to suffer permanent vision loss after developing non-arteritic anterior ischemic optic neuropathy (NAION), a condition that damages the optic nerve and can lead to blindness.

According to the complaint, the plaintiff began taking Ozempic injections in April 2024 and continued treatment for about a year before developing vision problems in both eyes.

The lawsuit claims Novo Nordisk failed to adequately warn patients and doctors about the growing evidence linking GLP-1 medications to NAION and other severe complications.

The case adds to a growing number of Ozempic vision loss lawsuits being filed nationwide as researchers continue to investigate whether semaglutide-based drugs increase the risk of optic nerve injuries.

Plaintiffs argue that the manufacturer aggressively marketed Ozempic and other GLP-1 drugs as transformative weight loss treatments while minimizing reports of serious side effects.

A wrongful death lawsuit involving Ozempic has been filed against Novo Nordisk.

The case involves a 76-year-old woman who allegedly developed persistent vomiting and stomach paralysis after several months of Ozempic use, ultimately leading to aspiration and death.

The lawsuit claims the manufacturer failed to adequately warn about the risk of serious gastrointestinal side effects.

These allegations mirror broader claims in the multidistrict litigation, where thousands of plaintiffs assert that GLP-1 drugs can cause severe digestive injuries such as gastroparesis, intestinal blockage, and prolonged vomiting.

Plaintiffs argue these risks were not sufficiently disclosed despite growing evidence and adverse event reports.

The litigation centers on core product liability issues, particularly whether the drug’s mechanism of slowing gastric emptying created foreseeable risks of serious harm and whether warnings and labeling adequately reflected those dangers.

The GLP-1 multidistrict litigation (MDL) recorded an increase of 90 newly filed cases between April and May, bringing the total number of pending cases from 3,546 to 3,636.

A separate but related GLP-1 MDL focused on vision loss claims currently includes 86 pending cases.

The steady rise in filings reflects ongoing legal activity, as individuals who used GLP-1 receptor agonist medications (including Ozempic, Wegovy, Rybelsus, Saxenda, and Mounjaro) continue to file lawsuits alleging severe gastrointestinal injuries, including gastroparesis, intestinal blockages, and other digestive complications.

If you or a loved one suffered from gastrointestinal issues or vision loss after taking GLP-1 medications, you may be eligible to file a lawsuit against the drug makers.

Contact the GLP-1 attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file a lawsuit instantly.

A recent study from Johns Hopkins University researchers has raised questions about whether widely prescribed GLP-1 receptor agonists, including Ozempic, Wegovy, and Mounjaro, may be associated with an increased risk of dementia and Alzheimer’s disease.

The study reviewed patient data to evaluate long term neurological outcomes among individuals using GLP-1 medications for diabetes and weight loss.

While some results suggested a possible signal related to cognitive decline, the data remain inconclusive and require further investigation.

Researchers noted that confounding factors such as underlying metabolic conditions, age, and preexisting health risks may influence the observed outcomes.

At the same time, other clinical and observational studies have reported neutral or potentially protective effects of GLP-1 drugs on brain health.

Some research suggests these medications may reduce inflammation and improve insulin signaling in the brain, which are mechanisms believed to play a role in neurodegenerative diseases.

However, large scale clinical trials have not demonstrated a clear benefit in slowing or preventing Alzheimer’s progression.

The conflicting findings highlight the early stage of research into the neurological effects of GLP-1 drugs.

Regulatory agencies have not issued warnings linking these medications to dementia or Alzheimer’s disease, and the current body of evidence does not establish that they increase cognitive risk.

Litigation involving GLP-1 drugs is currently focused on gastrointestinal issues related to the drugs, as well as vision loss in some individuals.

A new lawsuit filed on April 10 in Texas claims that a compounded semaglutide product caused a fatal overdose, raising fresh concerns about the safety of GLP-1 drugs sold by compounding pharmacies.

The complaint, brought by the family of Shawna Stash, alleges that Empower Clinic Services LLC sold a contaminated injectable semaglutide that caused her death in April 2024.

The plaintiffs seek class action status, citing reports that the pharmacy dispenses medications to thousands of patients daily.

The filing relies heavily on prior regulatory action against Empower, including an FDA warning letter issued after inspectors found that drugs were not stored under sterile conditions.

The lawsuit also cites enforcement actions in multiple states and a separate 2025 lawsuit that accuses the company of selling counterfeit GLP-1 drugs.

According to the complaint, these issues show that the pharmacy knew about quality risks but continued to sell the products.

While most current MDL proceedings focus on manufacturers and failure-to-warn claims, this lawsuit targets the safety and handling of compounded products.

According to a complaint filed April 10, 2026 by Lauren Stash and Don Rhodes on behalf of the estate of Shawna Stash, a GLP-1 Wrongful Death Lawsuit alleges Empower Clinic Services LLC, doing business as Empower Pharmacy, supplied a contaminated compounded semaglutide/cyanocobalamin injectable product.

The lawsuit states Shawna Stash died in April 2024 after receiving the compounded medication, with allegations that overdose and exposure to contaminants in the product contributed to her death. The complaint asserts the compounded formulation contained chemical impurities or other contaminants that rendered the medication unsafe for patient use.

Semaglutide serves as the active ingredient in Ozempic and Wegovy, medications prescribed for Type 2 diabetes and weight management. The drug belongs to the GLP-1 receptor agonist class, which includes medications such as Mounjaro, Zepbound, Trulicity, Rybelsus, Saxenda, and Victoza.

Rising demand for GLP-1 drugs has led to widespread supply shortages, resulting in increased use of compounding pharmacies to produce alternative versions of semaglutide formulations.

Empower Pharmacy appears in the complaint as a provider of compounded semaglutide during the period of increased market demand.

The allegations center on product quality and sterility standards in compounded GLP-1 medications, with the family asserting the compounded injection differed in safety profile from FDA-approved versions of semaglutide products.

A recent study conducted by researchers at the University of Pennsylvania analyzed more than 400,000 Reddit posts to identify patient-reported side effects associated with GLP-1 drugs, including Ozempic (semaglutide) and tirzepatide.

The study reviewed posts from approximately 70,000 users over several years. Researchers found that about 44% of users reported at least one side effect, with gastrointestinal symptoms remaining the most common.

The analysis also identified additional symptoms that may warrant further investigation, including reproductive issues such as irregular menstrual cycles and temperature-related complaints such as chills and hot flashes.

Researchers emphasized that the findings do not establish causation.

Clinical trials remain the primary method for determining drug safety and efficacy.

The study highlights that patient-reported data from social media may capture experiences that are not consistently documented in formal adverse event reporting systems.

The study also identified fatigue as a frequently reported symptom, despite limited representation in clinical trial data.

Researchers noted that GLP-1 drugs interact with the hypothalamus, a part of the brain involved in hormone regulation, which may provide a basis for further investigation into reported symptoms.

A new study has found that gastrointestinal symptoms are the most frequently reported side effects associated with GLP-1 receptor agonist medications, including Ozempic, Wegovy, and Mounjaro.

The findings come as lawsuits are being filed nationwide, with plaintiffs alleging that manufacturers failed to adequately warn about the severity and persistence of certain digestive complications.

According to the study, the most common adverse effects reported by patients include nausea, vomiting, diarrhea, constipation, and abdominal pain.

These symptoms are consistent with the drugs’ mechanism of action, which slows gastric emptying to regulate blood sugar and reduce appetite.

While these effects are widely documented, the study reinforces that they remain the dominant category of reported side effects among users.

The ongoing litigation, however, centers on more serious gastrointestinal injuries.

Plaintiffs have raised concerns about conditions such as gastroparesis and intestinal obstruction, which may lead to prolonged or severe digestive dysfunction.

In some cases, individuals allege that symptoms persisted even after discontinuing the medication, requiring additional medical treatment or hospitalization.

As the number of filed cases continues to grow, courts are expected to further evaluate whether existing warnings sufficiently addressed the risks of long-term or irreversible gastrointestinal injury.

The Ozempic GLP-1 MDL added 183 cases between March and April, increasing from 3,363 to 3,546.

More and more individuals who have used GLP-1 medications like Ozempic, Wegovy, Rybelsus, Saxenda, Mounjaro, and others continue to file lawsuits over gastrointestinal injuries.

There is also a separate MDL centralized in the same court for eye injuries, vision loss, and blindness, specifically NAION.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic, you may be eligible to file an Ozempic lawsuit against the drug makers.

Contact the Ozempic attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic lawsuit instantly.

Judge Karen Marston has scheduled a Science Day for June 2, 2026, in the Ozempic and Wegovy MDL concerning vision loss.

In a March 16 order, she stated that each side will have 2.5 hours to present non-adversarial explanations of the science behind the claims, including the supposed link between semaglutide and NAION.

The presentations will not be included in the official record, and neither the transcript nor demonstratives can be used later for discovery, impeachment, or collateral attacks.

The hearing provides the court with an early view of the scientific issues that will probably influence future pretrial decisions in the litigation.

It also indicates that the MDL is entering a more substantive stage as Judge Marston gets ready to handle expert and causation issues before any bellwether trials.

Marston is also managing the separate GLP-1 stomach-paralysis MDL, where key bellwether cases are expected to be prioritized first and could serve as a guide for how the vision-loss claims unfold.

The FDA issued a warning letter on March 5 to Novo Nordisk after inspectors found the company had failed to properly report serious adverse events associated with Ozempic and Wegovy.

According to the agency, Novo Nordisk failed to submit certain incidents, including deaths, within the required 15-day period and improperly withheld reports they deemed not causally related to the drugs.

Federal regulators state that manufacturers are not permitted to decide whether an event must be reported.

Inspectors also pointed out flawed internal procedures for monitoring and assessing postmarketing safety data.

The findings increase pressure as GLP-1 litigation continues to grow.

Plaintiffs already allege that Novo Nordisk failed to warn about risks such as gastroparesis and vision loss.

The FDA’s stance on mandatory reporting could influence discovery, especially as attorneys examine which adverse events the company received and how it managed those reports.

New research suggests that GLP 1 medications used for diabetes and weight loss may increase the risk of bone fractures and gout, adding to ongoing safety concerns that have already prompted product liability lawsuits against drug manufacturers.

Researchers recently reported findings indicating that patients using GLP 1 receptor agonists experienced higher rates of certain bone and joint conditions compared to non users.

The analysis found increased diagnoses of osteoporosis and osteomalacia, both conditions that weaken bones and raise the likelihood of fractures.

The study also observed a modest rise in gout cases among patients taking the medications.

The medications evaluated include widely used drugs such as Ozempic, Wegovy, and Mounjaro, which are prescribed to treat type 2 diabetes and are increasingly used for weight loss.

Researchers suggest the risks may be related to rapid weight loss, changes in metabolism, or reduced nutrient intake that can affect bone density and uric acid levels.

While the findings do not establish that GLP 1 medications directly cause bone disease or gout, they add to a growing body of research examining potential complications associated with the drugs.

The new research may increase scrutiny of the drugs as litigation continues and regulators and medical experts evaluate their long term safety profile.

The U.S. Food and Drug Administration sent warning letters Tuesday to 30 telehealth companies regarding the online sale and promotion of compounded GLP-1 drugs, including semaglutide and tirzepatide.

The agency stated that several companies made false or misleading claims on their websites, including suggesting their compounded products were the same as FDA-approved medications or implying they had been evaluated for safety and effectiveness.

Based on the letters, compounded GLP-1 drugs are not FDA-approved and cannot be marketed on a large scale once the branded versions are no longer in short supply.

The FDA stated that some companies also failed to clearly disclose the manufacturing locations of the compounded drugs.

Companies receiving letters include Kin Meds, GoodGirlRx, WeightCare, and PharmaZee.

The agency directed recipients to submit plans to address the violations, which could include revising marketing claims, providing product labels, and identifying the compounders supplying the medications.

The warning letters represent the FDA’s second wave of enforcement efforts against compounded GLP-1 promotions, as regulators intensify their oversight of telehealth platforms selling weight-loss medications online.

The crackdown follows federal officials’ referral of telehealth provider Hims & Hers to the Department of Justice for possible criminal violations related to the sale of compounded GLP-1.

Multiple lawsuits alleging vision loss from GLP‑1 drugs, including Ozempic, Wegovy, and Mounjaro have been consolidated into a multidistrict litigation in the Eastern District of Pennsylvania, the same court responsible for handling GLP-1 lawsuits involving gastrointestinal injuries.

The GLP-1 vision loss lawsuits primarily involve claims of non‑arteritic anterior ischemic optic neuropathy (NAION), a serious eye condition that can cause sudden blurred vision or permanent vision loss.

The court has appointed a leadership structure to manage the litigation, including co‑lead counsel, a plaintiffs’ executive committee, and liaison counsel.

These attorneys will coordinate discovery, handle pretrial motions, and oversee the selection of early bellwether cases to guide the resolution of other claims.

Plaintiffs allege that manufacturers failed to adequately warn about the risk of vision loss associated with these medications.

The appointment of leadership signals the next phase of the litigation, with coordinated discovery and early trial preparation expected to move forward in the coming months.

The Ozempic litigation added 172 cases between February and March, increasing from 3,191 to 3,363.

More and more people who have suffered gastrointestinal injuries from GLP-1 drugs are joining the litigation.

The court continues to oversee coordinated discovery and pretrial proceedings within the federal multidistrict litigation.

The Ozempic lawsuits focus on claims that manufacturers failed to adequately warn about the risk of delayed gastric emptying and long-term digestive complications associated with the drug.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic, you may be eligible to file an Ozempic Lawsuit against the drug makers.

Contact the Ozempic Attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

A proposed class action filed in Illinois federal court alleges that Hims & Hers Health Inc. falsely advertised its compounded GLP-1 injections as containing the “same active ingredient” as brand-name weight loss drugs Ozempic and Wegovy, despite differences in formulation and regulatory status.

The named plaintiffs claim the telehealth company’s compounded product is materially different from FDA-approved semaglutide medications and was not subject to the same safety testing or approval process.

According to the complaint, consumers were led to believe the compounded injections were equivalent to the branded drugs, when in fact they allegedly contained additional ingredients and were produced through a different process.

The suit contends that reasonable consumers would have been less likely to purchase or inject the compounded product had they understood the distinctions in composition and regulatory oversight.

Plaintiffs further allege that Hims promoted the product through website, television, and social media advertisements that referenced the “same active ingredient” as Ozempic and Wegovy and highlighted partnerships with FDA-regulated pharmacies.

The filing comes amid broader scrutiny of compounded GLP-1 products.

Federal regulators previously permitted compounded versions of semaglutide during a drug shortage, but that flexibility narrows once the shortage designation is lifted.

The complaint references regulatory developments and prior warnings regarding marketing representations, as well as recent disputes involving branded drug manufacturers.

The proposed class action asserts claims centered on false advertising and consumer protection theories.

If certified, the case could test how courts evaluate marketing language for compounded medications and the extent to which telehealth platforms must distinguish between FDA-approved drugs and compounded alternatives.

Hims & Hers has not publicly responded to the allegations in the newly filed complaint.

A recent study found that semaglutide drugs, including Ozempic and Wegovy, may increase the risk of non‑arteritic anterior ischemic optic neuropathy (NAION), a rare condition that can cause sudden, permanent vision loss.

The risk appears higher compared with SGLT2i diabetes medications, though NAION remains uncommon.

Patients experiencing sudden vision changes are advised to seek immediate medical evaluation.

Two separate multidistrict litigations have been formed to handle injury claims related to GLP-1 drugs.

One of the MDLs is centered on gastrointestinal injuries associated with these drugs, while the other, smaller MDL is focused on NAION and vision loss.

Both litigations are overseen by the same judge in the same federal court.

No nationwide settlements for NAION claims have been reported, and the MDL remains in pretrial proceedings as courts and parties monitor emerging safety data and adverse event reports.

A new study published in the Journal of Medical Internet Research is drawing attention in the growing Ozempic litigation landscape.

Researchers from Rutgers Health analyzed publicly available patient reviews and found that many people taking Ozempic (semaglutide) for weight loss choose to continue the medication even when they experience unpleasant side effects.

What the Study Found

Researchers reviewed 60 anonymous user reports and found:

• 62% reported gastrointestinal side effects, including nausea, vomiting, constipation, and abdominal pain.
• Despite this, most users remained satisfied if they experienced significant weight loss or appetite reduction.
• Approximately 67% reported weight loss or reduced cravings, which strongly predicted their decision to stay on the drug.
• Diarrhea and abdominal pain were more likely to lead to discontinuation than nausea alone.

The study concluded that for many users, the benefits of weight loss outweigh short-term discomfort.

Why This Matters for Ozempic Litigation

Ozempic lawsuits focus largely on whether Novo Nordisk adequately warned patients about more serious risks linked to GLP-1 drugs, including:

• Gastroparesis (stomach paralysis)
• Severe gastrointestinal injury
• Pancreatitis
• Gallbladder complications
• Vision issues
• Kidney injury

While the Rutgers study suggests many patients tolerate common GI side effects, it does not address long-term complications or permanent injuries, which are central to current product liability claims.

Plaintiffs in ongoing lawsuits argue that they were not properly warned about the risk of persistent stomach paralysis or other severe outcomes.

Defense arguments may point to research like this to show that many patients knowingly accept gastrointestinal discomfort as part of treatment.

However, legally, there is a significant difference between temporary nausea and chronic digestive injury that does not resolve after discontinuation.

The Bigger Picture

GLP-1 medications have surged in popularity, with polls suggesting that roughly 1 in 8 adults has tried a GLP-1 drug at some point.

As demand grows, so does scrutiny over labeling, informed consent, and risk disclosure.

This new study underscores one important reality: patients are highly motivated to lose weight and may tolerate side effects if they believe the drug is working.

In litigation, that dynamic raises questions about:

• What risks were clearly disclosed?
• Were long-term complications distinguishable from common temporary side effects?
• Did manufacturers update warnings promptly as adverse event reports increased?

As Ozempic cases move forward in federal courts, emerging research on patient experience will likely be cited by both sides.

But the core legal issue remains unchanged: whether consumers were adequately warned about the full scope of potential risks associated with semaglutide use.

More than 4,400 lawsuits have been filed in consolidated federal and state litigation since 2023, with additional filings expected.

The nonpartisan health policy organization KFF estimates that more than 31 million American adults use a GLP-1 medication.

Plaintiffs represent a small portion of total users, yet the lawsuits raise questions about the adequacy and timing of product warnings.

There are more than 110 plaintiffs alleging sudden blindness or major vision changes – lawsuits claim non-arteritic anterior ischemic optic neuropathy (NAION), sometimes described as an “eye stroke.”

A 2024 JAMA Ophthalmology study found an association between semaglutide and increased NAION risk, though researchers did not establish causation.

A European safety committee later required label language stating that NAION may occur in rare cases. U.S. labels warn of vision changes without naming NAION.

The Judicial Panel on Multidistrict Litigation consolidated many gastrointestinal injury claims into a federal multidistrict litigation in Pennsylvania.

Multidistrict litigation (MDL) is a procedure that groups similar federal lawsuits under one judge to coordinate pretrial proceedings.

A separate MDL was formed in late 2025 for vision injury claims.

State court cases continue in New Jersey, Indiana, and Delaware.

Defendants Novo Nordisk and Eli Lilly deny wrongdoing and state that FDA-approved labels already warn about severe gastrointestinal reactions.

Label updates in 2023 through 2025 added disclosures for ileus, intestinal obstruction, and other complications.

The U.S. Department of Health and Human Services (HHS) has referred Hims & Hers Health Inc. to the U.S. Department of Justice for investigation over potential violations of the federal Food, Drug, and Cosmetic Act.

The referral follows a public dispute between Novo Nordisk and the sale of compounded drugs marketed as alternatives to FDA-approved GLP-1 weight-loss medications, such as Wegovy.

The U.S. Food and Drug Administration (FDA) announced plans to pursue enforcement action against Hims & Hers and certain compounding pharmacies that sell compounded drugs containing GLP-1 ingredients. GLP-1 drugs are a class of medications used to treat diabetes and obesity by regulating appetite and blood sugar.

The FDA stated that compounded products cannot be marketed as generic equivalents to FDA-approved drugs and cannot claim the same active ingredients or clinical results.

The agency warned that violations may result in seizures or court injunctions.

Novo Nordisk threatened litigation after Hims & Hers announced the launch of a compounded pill marketed as containing the same active ingredients as Wegovy.

Novo Nordisk described the product as an unlawful mass-compounded version that could present safety risks.

Hims & Hers stated that the company complies with applicable law and plans to continue engaging with regulators.

Health officials and poison control centers are reporting a significant increase in overdose incidents involving widely used injectable weight loss medications, including GLP 1 drugs commonly prescribed for obesity and diabetes.

Reports indicate that calls to poison control related to these medications have risen sharply in recent years, raising concerns about dosing errors, misuse, and accidental exposure as the drugs become more prevalent in households.

Experts attribute the increase in reported overdoses to the rapid expansion of prescriptions and growing demand for these medications.

Some incidents involve patients mistakenly taking higher-than-recommended doses, confusion about injection instructions, or improper use of compounded or nonstandard formulations.

Public health officials have also raised concerns about accidental ingestion or exposure by children, highlighting risks tied to storage and handling.

The growing number of overdose reports is drawing attention from regulators, medical providers, and attorneys, particularly as litigation involving weight loss drugs continues to expand nationwide.

These developments may contribute to future claims alleging inadequate warnings, insufficient dosing instructions, or failure to address foreseeable risks tied to widespread consumer use.

As usage continues to climb, manufacturers and distributors may face increased legal scrutiny regarding whether they provided clear safety guidance and whether overdose risks were adequately disclosed to consumers and prescribing physicians.

The Ozempic GLP-1 receptor agonist MDL added 128 cases between January and February, increasing from 3,063 to 3,191.

The growth reflects continued plaintiff filings tied to gastrointestinal injury allegations.

The court remains focused on coordinated discovery and case management as the GLP-1 MDL continues to expand.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic, you may be eligible to file an Ozempic Lawsuit against the drug makers.

Contact the Ozempic Attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

New lawsuits are being filed alleging that the diabetes and weight loss drugs Ozempic and Wegovy caused severe and permanent vision loss, including blindness.

According to recent complaints, patients developed non arteritic anterior ischemic optic neuropathy, or NAION, after using the semaglutide based medications.

The lawsuits claim the injuries occurred without adequate warning to patients or prescribing physicians about the potential risk.

The cases name Novo Nordisk, the manufacturer of Ozempic and Wegovy, and assert that the company knew or should have known about a connection between semaglutide and optic nerve damage based on clinical data, post marketing reports, and emerging medical research.

Plaintiffs allege the drug labels failed to disclose the risk of NAION or other severe vision complications, depriving patients of the ability to make informed treatment decisions.

The complaints raise claims including failure to warn, negligence, defective design, and violations of consumer protection laws.

Plaintiffs are seeking consolidation to streamline discovery and address common factual questions, including what Novo Nordisk knew about potential eye related risks and when.

The Ozempic and GLP-1 litigation landscape is shifting after U.S. regulators asked drugmakers to remove suicide-related warnings from weight-loss and diabetes drugs, a move that is now drawing scrutiny from plaintiffs’ attorneys and safety experts.

Although regulators reviewed data from more than 90 clinical trials involving over 100,000 patients and found no statistically significant increase in suicidal thoughts compared to placebo, critics argue the decision comes too soon.

The concern is not what the trials showed, but what they could not capture.

Clinical trials are typically short, tightly controlled, and often exclude patients with histories of depression, anxiety, or suicidal ideation.

That leaves open questions about long-term and real-world risks.

This relates directly to Ozempic lawsuits against Novo Nordisk, which allege inadequate warnings about serious side effects.

Plaintiffs argue GLP-1 drugs like Ozempic act on the brain, altering appetite, reward systems, and impulse control.

Because these drugs affect the central nervous system, mental-health outcomes are a foreseeable safety issue, even if the precise level of risk remains uncertain.

From a litigation standpoint, label changes are not neutral.

Drug warnings shape how courts evaluate failure-to-warn claims.

If post-marketing data later suggests suicidal ideation occurs in certain users, plaintiffs are expected to argue that removing the warning prematurely reduced patient and physician awareness.

Courts often focus on what was known, what was foreseeable, and whether continued caution would have been reasonable.

Importantly, removing a warning does not eliminate liability.

In many product cases, it becomes evidence.

Plaintiffs may argue that the warning was dropped not because uncertainty was resolved, but because it was deprioritized as prescriptions surged and use expanded beyond the populations originally studied.

As Ozempic use continues to grow among millions of patients, the warning rollback adds a new layer to ongoing and future lawsuits.

The central question is no longer just whether a clear statistical link exists, but whether manufacturers and regulators exercised appropriate caution while long-term, real-world data is still developing.

A new federal multidistrict litigation docket has been established to centralize lawsuits alleging that glucagon‑like peptide‑1 (GLP‑1) receptor agonist drugs, including Ozempic, Wegovy, Rybelsus, Mounjaro, and others, caused serious vision loss linked to non‑arteritic anterior ischemic optic neuropathy (NAION).

The U.S. Judicial Panel on Multidistrict Litigation approved the creation of MDL No. 3163 In re: GLP‑1 Receptor Agonists Non‑Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation in December 2025.

This docket runs parallel to existing GLP‑1 MDL litigation that addresses other injury types, such as gastrointestinal harms.

Federal filings indicate that vision loss claims are being consolidated before the same judge overseeing the general GLP‑1 MDL in the Eastern District of Pennsylvania.

As of early 2026, there are 29 pending lawsuits in the NAION MDL attributable to alleged severe eye injuries following semaglutide and tirzepatide use.

Case management deadlines, including expert disclosures and discovery, are being established.

Plaintiffs in these actions allege that manufacturers, primarily Novo Nordisk and Eli Lilly, failed to adequately warn prescribers and consumers about the risk of NAION and sudden vision loss associated with GLP‑1 drugs.

Complaints filed across multiple districts include claims that the defendants knew or should have known about a potential association between GLP‑1 receptor agonists and optic nerve ischemia yet did not sufficiently update labeling or risk communication.

Separate from the federal MDL, state court litigation continues.

In New Jersey, a multicounty litigation has been organized for pretrial proceedings involving Ozempic and Wegovy vision loss claims.

Recent filings in other states underscore ongoing individual case activity outside centralized streams.

The overall landscape of GLP‑1 litigation remains active with filings steadily increasing.

The broader MDL addressing GLP‑1 drug injuries, including gastrointestinal and other systemic harms, reports over 3,000 total pending cases in federal court, reflecting continued claim growth across injury categories.

Discovery and case management phases are underway in the NAION MDL, with parties preparing to exchange expert evidence and establish preliminary litigation schedules.

No bellwether trials or settlements have been announced specific to the NAION docket as of this update.

The FDA announced on January 13 that it has asked Novo Nordisk and Eli Lilly to remove warnings about suicide and suicidal thoughts from the labels of Saxenda, Wegovy, and Zepbound.

The request comes after a safety review that analyzed nearly 100 placebo-controlled clinical trials with over 106,000 patients and found no increased risk of suicidal thoughts or behavior related to GLP-1 use.

The agency began its review in mid-2023 following reports of suicidal thoughts among some patients taking GLP-1 drugs for weight loss.

According to the FDA, the data showed no increased risk of suicide, depression, anxiety, or related psychiatric effects compared to placebo, leading the agency to conclude that the existing warnings are not supported by the evidence.

This development occurs as Novo Nordisk and Eli Lilly continue to defend against thousands of lawsuits claiming they failed to warn about other serious risks associated with GLP-1 drugs, including gastroparesis and vision loss.

Those claims remain concentrated in federal MDLs in Pennsylvania, where discovery and bellwether preparations are progressing.

The FDA’s decision limits the disputed risks but does not address the gastrointestinal and vision injury allegations fueling the current litigation.

U.S. District Judge Karen Marston convened the initial case management conference for the Ozempic blindness lawsuits in the Eastern District of Pennsylvania.

The conference followed the Judicial Panel on Multidistrict Litigation (JPML) transfer order consolidating federal claims alleging sudden vision loss from Ozempic, Wegovy, and related GLP-1 receptor agonist medications.

The MDL focuses on non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition linked to sudden vision impairment.

The consolidation allows coordinated discovery and pretrial proceedings while maintaining separation from ongoing Ozempic and other GLP-1 stomach paralysis lawsuits. Many claims involve overlapping defendants and counsel.

At the conference, parties reviewed preliminary position statements outlining factual and legal issues, pending motions, and related cases in federal and state courts.

Judge Marston addressed case census, discovery schedules, selection of lead counsel, complaint amendments, and future status conferences.

The court temporarily paused existing deadlines and discovery in pre-MDL filings.

Bellwether cases are expected to be selected for the Ozempic NAION MDL, following the framework used in GLP-1 gastroparesis litigation.

Bellwether trials provide early insight into how juries may respond to recurring evidence and testimony, which can influence broader settlement discussions.

The court also indicated that issues such as general causation and preemption must be resolved before trials proceed.

The MDL covers claims for Ozempic, Wegovy, Saxenda, and Mounjaro, with lawsuits asserting failure to warn about severe side effects, including NAION, gastroparesis, intestinal obstructions, and hair loss.

Novo Nordisk is the primary defendant, with Eli Lilly implicated in related NAION claims involving Trulicity.

Judge Marston’s management of the MDL aligns with her oversight of thousands of GLP-1 stomach injury lawsuits. Parties are expected to continue coordinated discovery and pretrial preparations while evaluating potential settlement outcomes.

Litigation involving Novo Nordisk’s blockbuster diabetes and weight-loss drug Ozempic continues to expand, as courts oversee a growing wave of product liability, compounding, and regulatory disputes tied to GLP-1 medications.

The most closely watched Ozempic-related cases remain part of a federal multidistrict litigation in Pennsylvania, where more than 3,000 plaintiffs allege GLP-1 drugs caused gastroparesis, or stomach paralysis.

In 2025, the court allowed the core failure-to-warn claims to proceed but imposed strict evidentiary requirements, requiring objective diagnostic testing to confirm gastric injury.

Expert discovery in the MDL is set to close in March 2026, with bellwether trials expected later this year.

At the same time, Ozempic litigation has expanded beyond gastrointestinal injuries.

Separate lawsuits involving vision loss, blood clots, and other serious adverse events are moving forward outside the MDL, signaling broader scrutiny of GLP-1 safety warnings and risk disclosures.

Novo Nordisk is also aggressively pursuing legal action against sellers of compounded and so-called “knockoff” versions of Ozempic.

Since the FDA ended the official GLP-1 drug shortage, Novo has filed more than 130 lawsuits nationwide accusing pharmacies, clinics, and medical spas of illegally marketing compounded semaglutide as FDA-approved.

Courts have already issued dozens of permanent injunctions barring continued sales.

These enforcement actions run parallel to mounting regulatory pressure.

The FDA and several state attorneys general have issued warnings that there are currently no FDA-approved generic GLP-1 injections and that marketing compounded versions as equivalent to Ozempic may violate consumer protection laws.

Taken together, the Ozempic litigation landscape now spans personal injury claims, compounding crackdowns, patent disputes, and investor lawsuits.

As bellwether trials approach and courts continue to define liability standards, 2026 is shaping up to be a pivotal year for Ozempic and the broader GLP-1 litigation.

The Ozempic lawsuit recorded an increase in total multidistrict litigation (MDL) cases from December 2025 to January 2026.

The docket rose from 2,947 total cases in December 2025 to 3,063 total cases in January 2026, resulting in 116 new filings during the month.

The Ozempic lawsuit involves claims that the diabetes and weight-loss drug Ozempic (semaglutide) caused gastrointestinal injuries, pancreatitis, and other health complications.

Plaintiffs allege that the manufacturer failed to provide adequate warnings about the risk of serious side effects associated with Ozempic use.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic, you may be eligible to file an Ozempic Lawsuit against the drug makers.

Contact the Ozempic Attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

The Judicial Panel on Multidistrict Litigation has ordered all federal lawsuits alleging vision loss from Ozempic, Wegovy, and related GLP-1 drugs to be centralized in the Eastern District of Pennsylvania.

The panel presented the cases to U.S. District Judge Karen Marston, who already handles the extensive GLP-1 stomach paralysis MDL, but established a separate MDL for the vision injury claims.

The new MDL currently includes at least 21 lawsuits filed by former users who claim the drugs caused non-arteritic anterior ischemic optic neuropathy (NAION).

This condition can lead to irreversible vision loss or blindness.

The JPML agreed with arguments that the NAION cases share common defendants, counsel, and overlapping scientific issues with the gastrointestinal injury litigation already pending before Judge Marston.

By assigning both MDLs to the same judge, the panel stated the court can decide the appropriate level of coordination while keeping the vision-loss claims on a separate track.

The decision establishes the procedural framework for early motions, discovery planning, and potential coordination with the ongoing GLP-1 stomach injury proceedings as the NAION litigation progresses.

A new peer-reviewed study published on November 26 in JAMA Otolaryngology – Head & Neck Surgery reports that GLP-1 medications, including Ozempic and Mounjaro, are associated with a higher incidence of chronic cough compared to several other commonly used second-line diabetes drugs.

The researchers examined records from over 427,000 patients across 70 health systems.

They found that GLP-1 users experienced chronic cough approximately 29% more often than patients taking alternatives such as DPP-4 inhibitors, SGLT2 inhibitors, and sulfonylureas.

The authors mention that the link requires more confirmation but consider it one of the first large-scale studies of cough risk in patients without GERD.

The Ozempic lawsuit recorded an increase in total multidistrict litigation (MDL) cases from November 2025 to December 2025.

The docket rose from 2,914 cases in November 2025 to 2,947 cases in December 2025, a total of 33 new filings.

The Ozempic lawsuit involves allegations that the diabetes medication Ozempic caused severe gastrointestinal issues, pancreatitis, thyroid tumors, or other adverse health effects.

Plaintiffs assert that prescribing information and product labeling failed to adequately warn patients and healthcare providers about these potential risks.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic, you may be eligible to file an Ozempic Lawsuit against the drug makers.

Contact the Ozempic Attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

A newly published study has intensified scrutiny over GLP-1 receptor agonists like Ozempic, Mounjaro, and Trulicity, linking them to significantly higher rates of gastrointestinal side effects compared to older diabetes medications.

Researchers from Brigham and Women’s Hospital and Harvard Medical School found that these drugs are associated with increased risks of gastroparesis (stomach paralysis), bowel obstruction, and pancreatitis.

Mounjaro posed the most significant risk, with users facing more than a 50% higher likelihood of serious GI complications compared to SGLT-2 inhibitors like Januvia and Farxiga.

This data supports claims raised in a growing number of lawsuits filed against manufacturers, including Novo Nordisk and Eli Lilly.

Plaintiffs allege the drugmakers failed to adequately warn about the severity of GI side effects while aggressively promoting these medications for both diabetes management and off-label weight loss.

The litigation continues to expand as additional users report life-altering complications. Many of the suits accuse the companies of prioritizing sales over safety and failing to update labels to reflect known risks.

As evidence builds, including real-world injury reports and now peer-reviewed clinical research, attorneys expect a wave of additional claims in the coming months involving Ozempic, Wegovy, Mounjaro, Zepbound, and other GLP-1 drugs.

The New Jersey Supreme Court has appointed two separate multicounty litigations (MCLs) for GLP-1 injuries, one for gastrointestinal injuries and the other for NAION-related vision loss, and transferred both to Bergen County before Judge Gregg A. Padovano.

The orders cover all pending and future New Jersey state court cases against Novo Nordisk and Eli Lilly related to GLP-1 drugs such as Ozempic, Wegovy, Rybelsus, Trulicity, Mounjaro, and Zepbound.

The NAION MCL follows a number of filings by plaintiffs who allege Ozempic and Wegovy caused permanent vision loss and cite recent research linking semaglutide to a significantly increased risk of non-arteritic anterior ischemic optic neuropathy.

Plaintiffs asked the court to keep the vision cases separate from GLP-1 gastrointestinal claims, which already include at least two dozen New Jersey cases alleging stomach paralysis, obstruction, and related injuries, while still benefiting from coordinated management under a single judge.

In federal court, GLP-1 gastrointestinal claims are still consolidated in MDL No. 3094 in the Eastern District of Pennsylvania before Judge Karen Spencer Marston.

The MDL now includes thousands of cases, and in an August 15, 2025 memorandum, Judge Marston set strict diagnostic requirements for gastroparesis claims, instructing plaintiffs to prove the condition with objective gastric emptying tests rather than symptoms alone.

Issues related to general causation and preemption are still being litigated, and bellwether trials have not yet been set.

A federal panel has transferred three additional New Jersey lawsuits into the expanding multidistrict litigation accusing Eli Lilly and Novo Nordisk of downplaying serious side effects linked to popular GLP-1 drugs such as Ozempic, Wegovy, Mounjaro, and Trulicity.

Plaintiffs across the MDL allege the drugmakers failed to warn about severe gastrointestinal injuries and other risks associated with GLP-1 receptor agonists.

The new transfers indicate continued national growth of the litigation as more patients come forward reporting long-term complications that were not adequately disclosed before use.

The Ozempic lawsuit saw case totals rise from 2,809 in October to 2,914 in November.

Plaintiffs allege that the drug, prescribed for type 2 diabetes and weight loss, caused serious gastrointestinal complications, including gastroparesis.

Litigation continues to develop as more individuals come forward with claims involving GLP-1 receptor agonists.

These filings are part of a larger trend involving similar drugs like Wegovy and Mounjaro.

Judicial coordination remains ongoing as the MDL progresses.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic, you may be eligible to file an Ozempic Lawsuit against the drug makers.

Contact the Ozempic Attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

A recent study suggests a potential link between Ozempic (semaglutide) use and non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition that can cause sudden, permanent vision loss.

Researchers analyzed data from over 100,000 individuals with diabetes and reported that users of GLP-1 receptor agonists like Ozempic may face an increased risk of developing NAION compared to those on other diabetes treatments.

The European Medicines Agency (EMA) has classified NAION as a very rare side effect of semaglutide, affecting up to 1 in 10,000 users.

Conflicting evidence exists, with some studies finding no increased risk among semaglutide users.

Patients experiencing sudden vision changes while using Ozempic are advised to seek immediate medical attention.

Some patients have already filed Ozempic blindness and vision loss lawsuits.

Plaintiffs in the growing litigation over GLP-1 drugs are asking the U.S. Judicial Panel on Multidistrict Litigation (JPML) to create a separate MDL for vision loss lawsuits, rather than merging them into the existing federal MDL for stomach paralysis and gastroparesis claims.

While about 3,000 cases are already pending in the consolidated gastrointestinal litigation before Judge Karen S. Marston in the Eastern District of Pennsylvania.

Dozens of new lawsuits allege that Ozempic, Wegovy, and Mounjaro caused a rare form of vision damage known as nonarteritic anterior ischemic optic neuropathy (NAION).

The push for a standalone MDL follows research from Harvard and JAMA Ophthalmology indicating that GLP-1 drugs may increase the risk of NAION up to sevenfold.

Plaintiffs argue that vision loss claims rely on distinct evidence and expert testimony unrelated to stomach paralysis and that combining them would delay progress for victims who have suffered blindness or serious visual impairment.

Most filings to date have originated in New Jersey federal court, where plaintiffs propose the new MDL should be centralized.

Drugmakers Eli Lilly and Novo Nordisk, however, maintain that the gastrointestinal and vision loss suits share overlapping factual and regulatory issues and should remain under one judge.

The JPML has not yet ruled on consolidation but is expected to take up the matter at its December 4 hearing.

Emerging research shows that GLP-1 weight-loss drugs like Ozempic, Wegovy, and Mounjaro may distort PET-CT scan results by altering tissue uptake of radioactive tracers, an effect that could mask tumors or make healthy tissue appear diseased.

Such “hotspot interference” is being reported more frequently, and radiologists warn it might lead to misdiagnoses, unnecessary follow-up procedures, or delayed treatment.

Though these findings stem from overseas imaging networks, they carry significant implications for patients and healthcare professionals.

The Ozempic lawsuit saw continued growth between September and October, increasing from 2,676 to 2,809 pending cases.

This increase of 133 cases reflects ongoing interest in claims linking GLP-1 receptor agonists, including Ozempic, Wegovy, Mounjaro, and others, to severe gastrointestinal injuries.

Plaintiffs allege that these medications can cause gastroparesis, intestinal blockages, and persistent vomiting, and that manufacturers failed to adequately warn users.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic, you may be eligible to file an Ozempic Lawsuit against the drug makers.

Contact the Ozempic Attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

A new study in JAMA Oncology warns that GLP-1 receptor agonists like Ozempic and Mounjaro may raise the risk of kidney cancer, even though they seem to lower the risk of other cancers.

Researchers from the Regenstrief Institute and the University of Florida analyzed data from nearly 87,000 adults participating in clinical trials conducted between 2014 and 2024.

They identified a 38% increased risk of kidney cancer among GLP-1 users compared to non-users, a finding described as “marginally nonsignificant” but nonetheless concerning given the widespread use of these drugs.

The findings come as more than 2,400 lawsuits over severe gastrointestinal side effects of Ozempic, Mounjaro, and similar medications continue in multidistrict litigation before Judge Karen Marston in the Eastern District of Pennsylvania.

The court is currently addressing broad issues of preemption and general causation before selecting bellwether cases.

These early trials will help assess how juries react to evidence about the safety of GLP-1 drugs and are expected to impact potential settlement talks.

The number of pending Ozempic lawsuits continued to rise between August and September.

According to the Judicial Panel on Multidistrict Litigation (JPML), 2,676 cases are now consolidated, compared to 2,190 in August.

This marks an increase of nearly 500 filings in a single month.

The lawsuits allege that Ozempic and related GLP-1 receptor agonist medications, including Wegovy and Mounjaro, caused severe gastrointestinal injuries such as gastroparesis, also known as stomach paralysis.

Plaintiffs claim the manufacturers failed to adequately warn patients and healthcare providers about these risks.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic, you may be eligible to file an Ozempic Lawsuit against the drug makers.

Contact the Ozempic Attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

U.S. District Judge Karen Marston has ruled that plaintiffs in the Ozempic and related GLP-1 litigation must confirm gastroparesis diagnoses with a gastric emptying study.

The order issued on August 15 establishes a clear evidentiary requirement for all plaintiffs pursuing gastroparesis claims in the MDL.

Plaintiffs argued that other diagnostic methods should be accepted. Still, Judge Marston determined that a gastric emptying study, via scintigraphy, breath test, or wireless motility capsule, is necessary to ensure reliability.

The court observed that most reported cases involve ongoing gastroparesis, meaning plaintiffs can still undergo testing and amend their complaints.

While this ruling may exclude some claims based on prior diagnoses, it allows the MDL to move forward.

Once the remaining cross-cutting issues, including federal preemption and general causation, are resolved, the court is expected to schedule bellwether trials to assess jury reactions and potentially influence future settlements.

Over 2,400 lawsuits are still consolidated in the Eastern District of Pennsylvania.

A federal court has allowed the majority of claims in the multidistrict litigation (MDL) against Eli Lilly and Novo Nordisk over the weight-loss drugs Ozempic and Wegovy to proceed, rejecting defendants’ attempts to dismiss them.

Plaintiffs allege the companies misled consumers about the risks associated with the drugs, including potential side effects and safety concerns.

While some claims were dismissed or excluded from the MDL, most will continue under the consolidated litigation framework.

The decision means discovery, pretrial motions, and potential settlement discussions will move forward.

The parties are now expected to focus on evidence gathering and expert witness preparation.

No trial dates have been set at this stage.

The FDA has issued a warning about serious safety risks linked to unapproved and compounded versions of GLP-1 receptor agonists, including semaglutide (the active ingredient in Ozempic and Wegovy).

These drugs, often used for weight loss, have been associated with hundreds of adverse event reports, some requiring hospitalization.

As of July 31, 2025, the FDA has received:

• 605 adverse event reports tied to compounded semaglutide
• 545 adverse event reports tied to compounded tirzepatide

Some of these reports involve serious reactions such as nausea, vomiting, abdominal pain, constipation, and dosing errors, especially when patients or providers miscalculate injections or exceed FDA-approved dosing schedules.

The agency is also investigating fraudulent compounded drugs and counterfeit Ozempic circulating in the U.S. market.

In multiple instances, product labels included false pharmacy names or referenced licensed pharmacies that never made the drugs.

In at least one case, a patient suffered injection site complications from a mislabeled product not made by the pharmacy listed.

The FDA emphasizes that many compounded semaglutide products may use salt forms (such as semaglutide sodium or acetate), which differ from the active ingredients in approved formulations and lack evidence of safety or efficacy.

Consumers are urged to avoid:

• Drugs marketed as “for research only” or “not for human consumption”
• Products sold through unauthorized online retailers
• Any medication without a valid prescription and pharmacy verification

Due to regulatory limitations, adverse event reports from state-licensed compounding pharmacies are often underreported.

However, the volume and severity of recent complaints have escalated concerns about legal accountability for unsafe and misbranded versions of GLP-1 drugs.

These findings may fuel additional product liability lawsuits against manufacturers and compounders, particularly in cases involving hospitalization, off-label dosing harm, or counterfeit exposure.

A new University of Utah Health study raises questions about potential muscle effects linked to the GLP-1 drugs, including decreased strength in some muscles despite minimal size loss.

Researchers found that in mice, semaglutide-induced weight loss mainly came from lean mass in organs like the liver, but some muscles showed decreased strength even without significant size loss.

The findings highlight concerns for older adults and others vulnerable to muscle weakness.

No human data yet confirms these effects, but the authors have stressed the need for clinical trials.

Novo Nordisk has intensified its legal campaign to protect the Ozempic® trademark, filing 14 additional federal lawsuits against pharmacies, telehealth providers, and other sellers marketing compounded semaglutide products.

The new filings bring the total to 132 lawsuits across 40 states.

The complaints allege that defendants falsely claim their compounded semaglutide products are equivalent to, or as effective as, the FDA-approved Ozempic®, creating a risk of consumer confusion and potential safety issues.

Novo Nordisk asserts that these products may contain unapproved or unregulated active pharmaceutical ingredients.

Courts have granted 44 permanent injunctions in related cases, prohibiting certain defendants from producing or marketing compounded semaglutide as comparable to Ozempic® or Wegovy®.

Some rulings have also required defendants to forfeit profits tied to the alleged trademark violations.

The litigation follows FDA safety warnings about compounded semaglutide, which the agency does not review for safety or efficacy.

The FDA has cited reports of overdoses and other adverse events linked to such products.

Novo Nordisk has also launched public awareness efforts, including the “Check Before You Inject” campaign and the website semaglutide.com, to inform consumers about the risks of non-FDA-approved alternatives.

Recent studies have identified a potential link between GLP-1 receptor agonist drugs (such as Ozempic, Wegovy, and Mounjaro) and increased risks of serious eye conditions, including neovascular age-related macular degeneration (nAMD) and nonarteritic anterior ischemic optic neuropathy (NAION).

These findings have triggered a wave of new lawsuits alleging that manufacturers failed to adequately warn patients about vision loss risks.

A large observational study published in mid-2025 reported that diabetic patients using GLP-1 drugs experienced a two- to threefold increased risk of developing nAMD compared to non-users.

Although the absolute risk remains low, this association has raised concerns among medical experts and regulatory authorities.

Earlier research and case reports also suggest a significant rise in NAION cases among patients treated with semaglutide and tirzepatide, with some reports indicating up to a fourfold increase in risk.

The European Medicines Agency has recommended updating drug labels for semaglutide to include NAION as a very rare side effect, advising patients to seek immediate medical care if sudden vision changes occur.

In the United States, lawsuits related to GLP-1 drug-induced vision loss are emerging outside the initial multidistrict litigation focused on gastrointestinal injuries.

These cases are being filed in multiple jurisdictions, including a multicounty litigation in New Jersey.

Plaintiffs claim that manufacturers did not sufficiently disclose the risks of vision damage, resulting in serious and sometimes irreversible harm.

The Ozempic MDL grew to 2,190 pending cases between July and August, up from 1,997 in July.

The litigation continues to focus on allegations that GLP-1 drugs like Ozempic, Wegovy, and Mounjaro caused severe gastrointestinal injuries, including gastroparesis and intestinal obstruction.

Recent filings indicate ongoing disputes over the scope of medical record production and expert retention deadlines.

The court has yet to finalize a bellwether trial schedule.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic, you may be eligible to file an Ozempic Lawsuit against the drug makers.

Contact the Ozempic Attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

Litigation over Ozempic and Wegovy has expanded beyond gastrointestinal injuries, with over 30 plaintiffs now alleging that use of the drugs led to vision loss caused by nonarteritic anterior ischemic optic neuropathy (NAION),  a condition that can cause permanent blindness.

On July 28, 2025, plaintiffs filed a petition with the New Jersey Superior Court requesting that these Ozempic vision loss lawsuits be consolidated as multicounty litigation (MCL) in Middlesex County.

The goal is to streamline the growing number of cases, which are currently scattered across eight judges and involve plaintiffs from 13 different states.

The lawsuits claim that Novo Nordisk failed to warn patients and the medical community about the risk of NAION, despite growing evidence from multiple studies.

Allegations include failure to warn, defective design, inadequate testing, and violations of the New Jersey Consumer Fraud Act.

Lawyers argue that centralizing these cases will avoid duplication and ensure consistent rulings on shared issues of Novo Nordisk’s knowledge and warnings related to vision risks.

While this request covers only vision-related injuries, plaintiffs acknowledged a separate track may be needed if the court chooses to include existing gastrointestinal claims.

Public comments on the MCL petition are due by August 29, 2025.

U.K. medicines regulators are asking anyone hospitalized with acute pancreatitis after taking a GLP-1 drug to file a Yellow Card report as part of a new investigation into whether genetics influence who develops pancreas inflammation on these widely used diabetes and weight-loss medications.

The Medicines and Healthcare products Regulatory Agency (MHRA) and Genomics England have opened enrollment through the Yellow Card Biobank, which will collect clinical details and saliva DNA samples to study patient susceptibility and improve future prescribing safety.

The call follows a rise in U.K. Yellow Card reports.

Health authorities have logged hundreds of suspected acute pancreatitis cases tied to GLP-1 medicines (nearly half involving tirzepatide) with some fatalities reported.

Current patient leaflets list pancreatitis as an “uncommon” reaction (up to ~1 in 100 users), but regulators want more data to clarify risk.

Pancreatitis concerns are not new for the drug class.

U.S. regulators flagged severe and sometimes fatal pancreatitis cases in 2007-2008 for the earlier GLP-1 drug Byetta (exenatide) and advised clinicians to stop therapy if patients develop persistent severe abdominal pain radiating to the back

In the United States, nearly 2,000 GLP-1 lawsuits—primarily alleging severe gastrointestinal injuries (gastroparesis, bowel obstruction, related complications) after Ozempic, Wegovy, Mounjaro, Trulicity, and other agents—are centralized in federal Multidistrict Litigation (MDL No. 3094) in the Eastern District of Pennsylvania.

While pancreatitis is not yet the lead injury in the MDL, emerging safety data from the U.K. investigation could influence future claims and labeling debates.

A new report from UAB Hospital highlights a significant rise in emergency department visits linked to GLP-1 medications, including Ozempic and Mounjaro.

The hospital reports that overdoses and adverse reactions are rising as more patients use weight loss drugs, many without prescriptions.

UAB physicians report that patients are arriving with dangerously low blood sugar, severe nausea, and even pancreatitis, sometimes after misuse of compounded or online versions of the drugs.

While not all reported cases involve off-label or non-prescribed use, doctors highlighted the dangers of unsupervised dosing and improper titration.

This rise in reported overdoses may influence ongoing litigation regarding GLP-1 drugs, where plaintiffs claim that manufacturers did not sufficiently warn about serious gastrointestinal and metabolic risks.

Reports like UAB’s could further bolster claims of inadequate guidance on safe use and dosing.

UK health regulators are investigating reports of pancreatitis linked to GLP-1 medications, including Ozempic (semaglutide), Wegovy (semaglutide), and Mounjaro (tirzepatide).

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has confirmed over 560 reports of acute or chronic pancreatitis in patients using these drugs, including 10 fatalities.

The MHRA has launched a genetic study in partnership with Genomics England to examine whether certain individuals may be genetically predisposed to developing pancreatitis after taking GLP-1 medications.

The agency is also encouraging patients and healthcare providers to report cases through its Yellow Card scheme and is collecting biological samples to aid in ongoing research.

This investigation is limited to the UK and is not currently part of the U.S. litigation involving these drugs.

Lawsuits filed in the U.S. primarily focus on other alleged side effects, such as gastrointestinal injuries, including gastroparesis and intestinal obstruction.

Pancreatitis-related claims are not formally included in the scope of the U.S. multidistrict litigation (MDL) at this time

A new lawsuit filed on July 10, 2025, in the U.S. District Court for the Southern District of New York alleges that use of Ozempic caused 85% vision loss in one eye due to non-arteritic anterior ischemic optic neuropathy (NAION).

Plaintiff Geoffrey Symonds claims he developed NAION after taking Ozempic for less than three months, from November 2021 to January 2022.

The lawsuit accuses manufacturer Novo Nordisk of failing to warn patients and healthcare providers of the potential risk of vision loss.

This case follows a growing number of claims linking GLP-1 receptor agonists—such as Ozempic, Wegovy, and Mounjaro—to NAION. In June 2025, 21 similar complaints were filed in New Jersey state court seeking consolidation into a multicounty litigation.

A separate Wegovy-related NAION lawsuit was also filed in New Jersey Superior Court the same month.

In June, the European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) concluded that NAION is a “very rare” side effect of semaglutide-based medications, recommending that vision risks be added to product warnings.

Recent studies from Harvard and other institutions suggest a significantly elevated risk of optic nerve damage among GLP-1 users, with some findings indicating a sevenfold increase in NAION diagnoses.

These vision loss claims remain separate from the federal multidistrict litigation (MDL 3094) involving gastrointestinal injuries allegedly caused by GLP-1 drugs, which is currently centralized in the Eastern District of Pennsylvania and includes over 1,900 cases.

Attorneys across the country continue to investigate potential vision-related injuries associated with GLP-1 agonists, including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound).

Ozempic is facing renewed safety concerns following reports of severe organ-related side effects, including pancreas, kidney, and gallbladder complications.

These developments may impact ongoing and potential litigation surrounding the drug.

Recent investigations by UK and U.S. health agencies have highlighted hundreds of cases of acute pancreatitis, some fatal, in individuals taking semaglutide-based medications such as Ozempic.

UK regulators are reportedly considering genetic screening measures to assess patient risk.

In the U.S., post-market surveillance data from 2005–2023 show over 6,700 cases of pancreatitis tied to GLP-1 drugs, leading to growing concern among healthcare providers and attorneys.

Other reported complications include acute kidney injury resulting from dehydration due to severe gastrointestinal side effects, such as vomiting and diarrhea.

The FDA has advised that kidney function should be monitored closely in high-risk patients.

Gallbladder issues, including gallstones and inflammation, have also been documented, with clinical trials showing higher incidence rates in Ozempic users compared to placebo.

In addition, the FDA has updated Ozempic’s label to include warnings about gastrointestinal obstruction and delayed gastric emptying (gastroparesis).

Emerging research has also linked long-term GLP-1 use to an elevated risk of vision problems.

While many of these side effects remain rare, the severity of outcomes has prompted increased regulatory scrutiny and legal interest.

Plaintiffs in current and potential lawsuits allege that manufacturers failed to adequately warn about serious risks associated with Ozempic and similar medications.

A growing number of lawsuits are being filed against Novo Nordisk alleging that its GLP-1 receptor agonist drugs, including Ozempic and Wegovy, caused users to suffer permanent vision loss due to non-arteritic anterior ischemic optic neuropathy (NAION).

These lawsuits are being filed independently across multiple jurisdictions and are not currently part of the existing multidistrict litigation (MDL) involving gastrointestinal injuries such as gastroparesis.

The increase in vision loss claims comes after emerging data—including a June 2025 JAMA Ophthalmology study—linked semaglutide use to significantly higher rates of NAION.

Plaintiffs allege the manufacturer failed to adequately warn about the potential for sudden and irreversible vision damage.

While the current GLP-1 drug MDL, established in the Eastern District of Pennsylvania, is focused on gastrointestinal injuries, the surge in NAION-related cases is raising the question of whether the scope of that MDL will be expanded to include additional categories of injury.

At this time, vision-related lawsuits remain outside the MDL, and no consolidation has been ordered.

However, as more claims are filed and adverse event reports continue to rise, the possibility of centralization or MDL expansion remains under consideration.

Novo Nordisk denies that a causal relationship exists between its semaglutide products and NAION and has not updated its warning labels to include vision loss as a known risk.

The Ozempic MDL grew to 1,997 total cases in July, up from 1,882 in June.

Plaintiffs continue to allege that Ozempic and other GLP-1 drugs caused severe gastrointestinal injuries such as gastroparesis, intestinal blockages, and persistent vomiting.

The court is actively managing early case proceedings, with bellwether trial selection and discovery frameworks under discussion.

Defense counsel is expected to contest causation, while plaintiffs seek access to internal safety data and adverse event reports.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic, you may be eligible to file an Ozempic Lawsuit against the drug makers.

Contact the Ozempic Attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

U.S. District Judge Mark Pittman has approved the FDA’s decision to remove semaglutide, the active ingredient in Ozempic and Wegovy, from its drug shortage list, dismissing a lawsuit filed by the Outsourcing Facilities Association. 

The ruling prevents compounding pharmacies from continuing to make copies of the popular weight-loss medications, which they had been permitted to do under FDA rules during the declared shortage.

Pittman found that the FDA had taken into account supply and demand data, including public comments from Novo Nordisk’s CEO regarding limited access to the drugs.

The court also observed that the FDA questioned the company about those statements before reaching a decision.

Larger outsourcing facilities were required to stop compounding drugs by May 22, while smaller pharmacies had to cease by April.

This is the second loss for compounding pharmacies challenging FDA decisions regarding weight-loss drugs.

In May, Pittman dismissed a similar lawsuit concerning the removal of Eli Lilly’s Zepbound and Mounjaro from the shortage list.

That ruling is presently under appeal.

The European Medicines Agency’s safety committee concluded that semaglutide, the active ingredient in Ozempic, Wegovy, and Rybelsus, may rarely cause non-arteritic anterior ischemic optic neuropathy (NAION).

This serious eye condition can lead to vision loss.

The EMA directed Novo Nordisk to update product labels to indicate NAION as a rare side effect, defined as occurring in up to 1 in 10,000 users after at least one year of treatment.

This marks the first time a regulatory authority has formally acknowledged the link, following multiple studies suggesting an increased risk of NAION among type-2 diabetes patients taking semaglutide.

A study conducted in March 2025 involving 350,000 patients found that two years of Ozempic use more than doubled the risk of developing the condition compared to alternative diabetes treatments.

Novo Nordisk stated that neither clinical trials nor post-marketing data suggest a “reasonable possibility” that semaglutide causes NAION.

Still, it said it will cooperate with the EMA to update the labels.

The company maintains that the benefit-risk profile remains favorable. U.S. regulators have not provided comments on whether the FDA is reviewing the issue.

Emerging reports suggest that GLP-1 medications, such as Ozempic and Wegovy, may impair fertility in both men and women, raising potential implications for future product liability claims.

Registered dietitian Ayla Barmmer told The New York Post that 15% of her GLP-1 patients have encountered fertility challenges, with 40% of that group experiencing irregular menstrual cycles, delayed ovulation, or declining sperm quality, outcomes likely tied to nutrient deficiencies resulting from rapid weight loss.

The issue is associated with significant deficiencies in protein, vitamin B12, vitamin D, iron, calcium, and folate, all of which are essential for reproductive health.

Some women have developed defects in the luteal phase, while men have experienced decreases in testosterone and sperm motility.

Clinicians have also noted that sudden caloric deficits can lead the brain to decrease reproductive hormone production as a protective mechanism.

However, GLP-1s have also been reported to improve fertility in some cases, particularly in patients with PCOS, due to their ability to enhance insulin sensitivity and reduce systemic inflammation.

This paradox highlights the complexity of potential reproductive side effects and may become relevant if claimants allege unexpected fertility harm or unsuccessful pregnancies.

Barmmer recommends that GLP-1 users planning to conceive undergo targeted nutrition therapy and consider tapering off the medication eight to ten weeks before attempting pregnancy.

The Ozempic MDL added 73 cases between May and June, bringing the total to 1,882.

New filings continue to center on gastroparesis, with plaintiffs reporting months-long vomiting, severe bloating, and repeated hospital visits after using GLP-1 receptor agonists like Ozempic and Wegovy.

Many complaints now include diagnostic imaging and gastroenterologist notes confirming delayed gastric emptying.

Lawyers are coordinating medical reviews to identify common usage patterns, including dosage escalation timelines and concurrent use with other GLP-1 drugs.

The court is expected to set initial discovery parameters in the coming weeks.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic, you may be eligible to file an Ozempic Lawsuit against the drug makers.

Contact the Ozempic Attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

Doctors and dentists are warning about “Ozempic teeth,” a term used for the dental issues increasingly reported by users of semaglutide.

Patients using Ozempic and other GLP-1 medications have reported tooth decay, gum irritation, enamel erosion, and ongoing dry mouth.

These issues seem to arise from common side effects such as dehydration, acid reflux, and vomiting, according to Dr. Sandip Sachar and Dr. Meghan Garcia-Webb.

There is no formal research connecting the drug to oral health complications.

Still, clinicians observe that reduced thirst and slower digestion—two known effects of GLP-1 medications—can lead to decreased saliva production.

The lack of saliva increases plaque buildup, making teeth more vulnerable to acid damage and decay.

Doctors suggest lowering the dose or adding medication to manage nausea if symptoms arise.

At this time, dental injuries are not accepted injuries in the Ozempic lawsuit. However, as more research is conducted and made public, attorneys will investigate and explore these potential injuries.

The FDA is now cracking down on compounded versions of popular weight-loss drugs like Ozempic and Zepbound, following the official end of nationwide shortages.

Compounded drugs are custom-made by pharmacies and have served as a lower-cost alternative during supply issues—often costing around $350 compared to $1,000 for the brand-name versions.

With shortages resolved, the FDA says these off-brand versions must stop production.

Officials warn that compounded semaglutide products may pose safety risks due to inconsistent dosing and lack of testing.

Some pharmacies have attempted to sidestep the crackdown by altering ingredients or dosages, raising further concern.

Doctors urge patients to use only FDA-approved medications and consult healthcare providers before starting or continuing any compounded weight-loss treatments.

As the popularity of GLP-1 receptor agonists such as Ozempic, Wegovy, and Zepbound increases, a newly reported complication known as “Ozempic feet” has become a growing concern.

This term refers to the physical changes in the feet that occur due to rapid and significant weight loss, which is often associated with these medications.

Specifically, users may experience a reduction in the natural fat padding on the soles of their feet, which can lead to discomfort, pain, and a sensation of walking directly on bone.

These changes can affect a person’s mobility and overall quality of life, potentially limiting their ability to remain active, which is essential for maintaining long-term health and preventing weight gain.

Medical professionals note that, although this condition is not life-threatening, it can lead to structural and functional issues in the feet.

The loss of cushioning may lead to increased pressure on bones, joints, and tendons, potentially altering a person’s walking pattern and adding strain to other body parts.

For individuals with preexisting conditions such as type 2 diabetes, this side effect may be particularly problematic.

People with diabetes already face increased risks of nerve damage, poor circulation, and ulcers, making it essential to monitor any new discomfort or changes in foot structure.

124 cases have been added to the Ozempic MDL in the past month.

This growth has been consistent throughout this year, with 478 cases added to the litigation since January 1st.

The rising number of claims reflects increasing awareness among users who have experienced painful and debilitating side effects.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic, you may be eligible to file an Ozempic Lawsuit against the drug makers.

Contact the Ozempic Attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

A new lawsuit has been filed, alleging that Ozempic has caused severe vision loss.

A North Carolina resident filed the lawsuit on April 16 in New Jersey federal court, claiming she developed blurred and reduced vision in her left eye after using Ozempic.

This lawsuit is filed outside of the federal GLP-1 multidistrict litigation (MDL) pending in the Eastern District of Pennsylvania.

Most existing lawsuits against the manufacturers of Ozempic, Wegovy, Mounjaro, and similar drugs involve allegations of gastroparesis, ileus, intestinal obstruction, and other gastrointestinal issues.

These cases have been consolidated under the supervision of U.S. District Judge Karen S. Marston, where the court is currently addressing cross-cutting issues, including federal preemption, the sufficiency of diagnostic evidence, and general causation linking GLP-1 drugs to gastrointestinal injuries.

This new complaint, along with a few others, centers on vision loss, alleging that Novo Nordisk failed to adequately warn users about the risk of developing non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition characterized by reduced blood flow to the optic nerve.

Concerns about Ozempic-related vision problems surfaced in July 2024 after a Harvard study indicated a significantly increased risk of NAION among semaglutide users.

Additional findings published in January 2025, along with actions taken by the Danish Medicines Agency, prompted further scrutiny of the drug’s vision-related side effects.

According to the lawsuit, the plaintiff used Ozempic between November 2023 and June 2024, leading to her NAION diagnosis.

She asserts claims of failure to warn, breach of warranty, fraudulent concealment, misrepresentation, design defect, negligence, and seeks both compensatory and punitive damages.

While the early bellwether trials in the GLP-1 MDL are expected to influence the broader litigation landscape and may pave the way for settlements, the vision loss lawsuit is a separate entity.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic, you may be eligible to file an Ozempic Lawsuit against the drug makers.

Contact the Ozempic Attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

The U.S. Food and Drug Administration (FDA) has released a public alert after the seizure of several hundred units of counterfeit Ozempic in the United States.

Patients and healthcare providers are encouraged to confirm the authenticity of their prescriptions because of the possible distribution of counterfeit 1-milligram Ozempic injections outside the authorized supply chain.

The counterfeit products were identified by the lot number PAR0362 and the serial numbers beginning with 51746517.

The FDA confiscated these units on April 9, 2025, and has launched an investigation in collaboration with Novo Nordisk, the manufacturer of Ozempic.

Initial reports suggest that six adverse events could be linked to the affected lot, although there is presently no confirmed connection to the counterfeit drugs.

Testing continues to assess the safety and composition of the seized products.

This incident underscores growing concerns regarding the widespread use and demand for Ozempic, particularly as it is being utilized off-label for weight loss.

This follows a similar warning issued by the FDA in December 2023, when thousands of counterfeit Ozempic units were seized, and some of these are believed to still be in circulation.

Counterfeit drugs are distinct from compounded versions, which pharmacies produce under specific regulatory allowances during drug shortages.

However, the FDA previously announced in February 2025 that the supply issues related to Ozempic and its weight loss counterpart, Wegovy, have been resolved, effectively decreasing the need for compounded alternatives.

The FDA and Novo Nordisk are continuing to monitor the situation and are taking steps to prevent the further distribution of unauthorized products.

Healthcare professionals are encouraged to report any suspected counterfeit medications.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic, you may be eligible to file an Ozempic Lawsuit against the drug makers.

Contact the Ozempic Attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

Pfizer has officially halted the development of its experimental once-daily weight loss pill, danuglipron, due to a case of liver injury in a clinical trial participant.

This decision arises as scrutiny over the safety of GLP-1 drugs, a class that includes Ozempic, intensifies amid the growing popularity and competition in the obesity treatment market.

Although the affected patient did not show liver-related symptoms, elevated liver enzyme levels were noted, a marker of potential liver damage.

According to Pfizer, the enzymes returned to normal after the patient ceased taking danuglipron.

This case occurred during a study in which the pill’s dosage was rapidly increased, and Pfizer stated that its decision was based on a thorough review of all clinical data and regulatory feedback.

This marks Pfizer’s second withdrawal of a danuglipron formulation, following the discontinuation of a twice-daily version in December 2023 due to tolerability issues.

Despite earlier confidence in the once-daily version, Pfizer has halted its development.

However, the company stated that its latest trials still met key goals related to efficacy and tolerability.

The GLP-1 drug class, which includes Ozempic (semaglutide), Wegovy, and Mounjaro, works by mimicking gut hormones to regulate blood sugar and reduce appetite.

These medications have garnered significant attention for their weight loss benefits.

While Ozempic is approved for the treatment of Type 2 diabetes, it has also been used off-label for weight loss.

Pfizer noted that the incidence of elevated liver enzymes with danuglipron was consistent with that observed in approved GLP-1 treatments.

The overall safety of GLP-1 drugs is still being monitored as more patients start long-term use.

Pfizer remains dedicated to developing obesity treatments and is currently exploring alternative drug candidates, including a GIPR-targeting oral therapy that is in phase two trials.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic, you may be eligible to file an Ozempic Lawsuit against the drug makers.

Contact the Ozempic Attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

A new study has identified a rare yet significant connection between the use of Ozempic and severe low blood sugar levels, even when the medication is taken alone.

These findings may impact ongoing legal reviews concerning the drug’s safety.

The research, conducted by the Centers for Disease Control and Prevention (CDC) and Cambridge Health Alliance, was published on April 7 in the Annals of Internal Medicine.

It examined emergency room visits associated with semaglutide drugs such as Ozempic and Wegovy.

From 2022 to 2023, approximately 24,500 emergency visits were linked to these drugs, with the majority, over 20,000, occurring in 2023.

Most visits were due to stomach issues such as nausea, vomiting, or diarrhea—typically resulting from incorrect dosing.

About 16% of cases involved low blood sugar, or hypoglycemia.

This condition can lead to serious health problems, including seizures, fainting, or stroke-like symptoms.

Low blood sugar typically poses a risk when medications like Ozempic are used alongside insulin or other drugs that reduce blood sugar levels.

However, this study identified a few instances where Ozempic was the sole medication used, yet low blood sugar still occurred.

There is also a growing concern about unapproved, compounded versions of semaglutide, which are often sold online during shortages of the official brand-name products.

Poison control centers have experienced a sharp rise in calls related to these versions, primarily because people are taking incorrect dosages.

Some accidentally took 10 times the appropriate dose because of confusing syringe instructions.

Since 2019, calls related to GLP-1 drugs like Ozempic have surged by 1,500%, with 1,678 cases already reported in 2025.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic, you may be eligible to file an Ozempic Lawsuit against the drug makers.

Contact the Ozempic Attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

In March, 1,521 total Ozempic Lawsuits were filed.

By April 1st, the JPML reported that the number of Ozempic Lawsuits grew to 1,685, marking an increase of 164 new filings.

The Ozempic Lawsuit centers around allegations that the use of the type 2 diabetes drug has led to severe side effects, including gastrointestinal issues, pancreatitis, and other serious health conditions.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic, you may be eligible to file an Ozempic Lawsuit against the drug makers.

Contact the Ozempic Attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

Plaintiffs in the growing litigation over GLP-1 medications like Ozempic, Wegovy, and Mounjaro have asked a federal judge to reject efforts by Novo Nordisk and Eli Lilly to dismiss most of the claims brought against them.

In a filing submitted March 18, plaintiffs argue that the drug makers overstated the benefits of GLP-1 drugs while minimizing the risk of serious gastrointestinal injuries, including gastroparesis, ileus, and intestinal obstruction.

More than 1,500 lawsuits have been consolidated before U.S. District Judge Karen Marston in the Eastern District of Pennsylvania, forming a multidistrict litigation (MDL) involving users of the diabetes and weight-loss drugs.

Plaintiffs allege the manufacturers failed to warn about life-altering GI complications while aggressively marketing the drugs as near-miracle weight-loss solutions.

In January, the manufacturers moved to dismiss most claims in the MDL’s Master Complaint, arguing that only the failure-to-warn claims may be valid.

But plaintiffs counter that their lawsuit details a much broader scheme of deceptive marketing, negligent misrepresentation, breach of warranty, and design defect.

“Defendants ignored known risks to maximize profits,” the filing states.

“Their campaign directly influenced patient decisions and altered prescribing behaviors through overstated promises and withheld safety data.”

The court still must resolve several cross-cutting issues, including whether the claims are preempted by federal law and whether plaintiffs need specific diagnostic testing to prove injury.

If the cases proceed, Judge Marston is expected to schedule bellwether trials to help evaluate how juries respond to the evidence.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic, you may be eligible to file an Ozempic Lawsuit against the drug makers.

Contact the Ozempic Attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

In recent months, a growing number of individuals who used GLP-1 medications like Ozempic, Mounjaro, and Wegovy for weight loss and Type 2 diabetes management have reported severe vision-related side effects, including non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition causing sudden and often irreversible vision loss.

Among those affected is James Norris, a 56-year-old mechanic, who experienced blurred vision in both eyes after using Mounjaro.

He had been prescribed the medication in 2023 and saw significant weight loss and improvement in his health, but within a year, his vision rapidly deteriorated.

Norris and others have now filed lawsuits against the manufacturers, including Novo Nordisk, the maker of Ozempic and Wegovy, and Lilly, the maker of Mounjaro.

Studies published in January and July 2024 showed an increased risk of NAION for patients using these drugs, with individuals who took them for weight loss at an even higher risk.

Despite these findings, the medications’ manufacturers have not added explicit warnings about NAION to their product labels, leaving patients unaware of the serious consequences.

The legal claims include accusations of deceptive marketing and failure to inform the medical community about the risks of vision impairment linked to the drugs.

Attorneys representing the plaintiffs argue that patients, who used these medications in good faith to manage their weight or diabetes, suffered devastating consequences without being informed of the potential for vision damage.

As more patients come forward with similar complaints, the number of lawsuits is expected to rise, creating growing pressure on the manufacturers to address the risks associated with their products.

Novo Nordisk and Lilly, in response to these allegations, have stated that they take patient safety seriously and continuously monitor the safety of their medications.

However, patients and their legal representatives argue that these actions came too late, and the lack of a clear warning on the drugs has resulted in life-altering consequences for many users.

This wave of lawsuits follows recent studies showing a clear correlation between these medications and an increased likelihood of developing serious eye conditions, with some cases leading to permanent blindness.

For patients like Cheryl Bovee, who is now legally blind after taking Ozempic, the medication’s benefits have been overshadowed by its devastating side effects.

Bovee, who filed her lawsuit against Novo Nordisk in February 2025, claims that the company’s marketing of Ozempic was misleading and deceptive, failing to disclose the potential for severe vision loss.

As these cases develop, more patients who have experienced vision issues while using Ozempic, Mounjaro, or Wegovy are expected to join the lawsuits.

The outcome of these legal actions could have significant implications for the pharmaceutical industry, potentially leading to new regulations around the labeling and marketing of medications used for weight loss and diabetes management.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic, you may be eligible to file an Ozempic Lawsuit against the drug makers.

Contact the Ozempic Attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

A federal judge has ruled against compounding pharmacies’ ability to produce their own versions of Eli Lilly’s diabetes and weight loss drugs, Zepbound and Mounjaro.

The decision, issued by Judge Mark Pittman of the Northern District of Texas, follows a lawsuit filed by the Outsourcing Facilities Association (OFA) in October.

The OFA claimed the FDA’s decision to remove tirzepatide, the active ingredient in these drugs, from its shortage list would deprive patients of vital treatments and raise drug prices.

This ruling effectively halts the production of compounded versions of these medications, which had been allowed during the shortage period.

The FDA had paused enforcement after the lawsuit was filed but reaffirmed its stance in December.

Smaller state-licensed pharmacies were given until February 18 to stop making compounded tirzepatide, and larger outsourcing facilities must cease production by March 19.

The OFA has signaled plans to appeal, with similar litigation ongoing regarding semaglutide, the active ingredient in Ozempic.

Eli Lilly praised the ruling, claiming it would eliminate risky, unapproved knockoffs of the drugs.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic, you may be eligible to file an Ozempic Lawsuit against the drug makers.

Contact the Ozempic Attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

After more than two years of supply issues, the shortage of Ozempic and Wegovy has officially ended, according to the FDA.

Novo Nordisk reports that production has stabilized, allowing the company to meet current and future demand in the U.S.

Despite this, some delays may persist as shipments move through distribution channels.

Patients should check with their pharmacies regarding availability.

Additionally, compounding pharmacies will be required to phase out off-brand versions of semaglutide in the coming months.

The resolution of supply issues comes as lawsuits continue to be filed against Novo Nordisk by individuals who suffered severe gastrointestinal injuries and other complications after taking Ozempic and other GLP-1 drugs.

These claims allege that the manufacturer failed to adequately warn consumers about the risks associated with the drug.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic, you may be eligible to file an Ozempic Lawsuit against the drug makers.

Contact the Ozempic Attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

In February 2025, the number of Ozempic lawsuit cases rose to 1,443, reflecting an increase of 112 cases compared to January 2025, where the total stood at 1,331.

This uptick in filings can be attributed to ongoing concerns regarding Ozempic’s side effects, with plaintiffs claiming various health complications caused by the medication.

The rise in litigation highlights growing awareness of potential risks associated with the drug and increased legal action from those affected.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic, you may be eligible to file an Ozempic Lawsuit against the drug makers.

Contact the Ozempic Attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

A recent study has raised alarm over websites selling compounded versions of popular weight-loss drugs, such as Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, often without disclosing crucial safety risks.

Researchers reviewed 79 websites advertising compounded GLP-1 receptor agonists, like semaglutide and tirzepatide, and found significant lapses in transparency.

Key Findings:

• Over half of the websites failed to disclose that their products were not FDA-approved.
• 37% misleadingly implied FDA approval, while 14% did not clarify they were selling compounded versions.
• Roughly 50% omitted critical information about side effects, precautions, and warnings.
• Around 40% overstated the benefits of these drugs, potentially creating false expectations.

The study highlights the risks associated with compounded drugs, which are often made during shortages of branded medications but lack FDA verification for safety or efficacy.

The ongoing tight supply of Wegovy and Zepbound has fueled demand for these alternatives, which are being sold at prices ranging from $231 to $330 for the first month.

Experts, including outgoing FDA Commissioner Robert Califf, have expressed concerns about the safety of internet compounding pharmacies, warning that patients may not know what they are purchasing.

Researchers and commentators have called for stricter oversight of advertisements for compounded drugs, urging them to meet the same standards as FDA-approved prescription medications.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic, you may be eligible to file an Ozempic Lawsuit against the drug makers.

Contact the Ozempic Attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

The federal multidistrict litigation (MDL) over Ozempic and other GLP-1 drugs continues to expand, now encompassing claims related to Saxenda but remaining focused on gastrointestinal injuries like gastroparesis, small bowel obstruction, and gallbladder issues.

A critical evidentiary hearing is set for May 14, 2025, where U.S. District Judge Karen Marston will evaluate whether plaintiffs have presented sound scientific evidence linking these drugs to alleged injuries.

This “cross-cutting” issue is pivotal, as plaintiffs must establish general causation to proceed with their claims.

Currently, the litigation includes over 1,300 lawsuits against Novo Nordisk and Eli Lilly, with numbers expected to grow as more individuals report complications like stomach paralysis and intestinal blockages.

Given the broad use of GLP-1 drugs, the scope of this MDL could reach tens of thousands of claims in 2025.

Regular status conferences will be held throughout the year, while fact discovery on causation is slated to conclude by July 2025.

Trials are not expected to begin until late 2026 or early 2027, with outcomes likely influencing future settlement negotiations.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic, you may be eligible to file an Ozempic Lawsuit against the drug makers.

Contact the Ozempic Attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

The Ozempic Lawsuit focuses on claims that the diabetes and weight loss medication Ozempic has caused severe gastrointestinal side effects, including gastroparesis, nausea, and vomiting.

Plaintiffs allege that the manufacturers of these drugs, Novo Nordisk and Eli Lily, failed to adequately warn users of these risks.

In December, 1,300 cases were pending in the Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation.

The number of Ozempic Lawsuits pending in the MDL has increased to 1,331 in January, with 31 new claims added.

Gastroparesis and related complications can significantly impact quality of life, often requiring ongoing medical intervention.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic, you may be eligible to file an Ozempic Lawsuit against the drug makers.

Contact the Ozempic Attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

The FDA has raised concerns about unapproved GLP-1 drugs like semaglutide (Ozempic) and tirzepatide being used for weight loss.

These compounded and counterfeit versions bypass FDA safety reviews, posing serious risks to patients.

Reports include severe side effects like nausea, vomiting, and even hospitalization due to dosing errors and improperly labeled products.

Compounded versions often use unauthorized ingredients, such as salt forms of semaglutide, or exceed approved dosage guidelines, further increasing risks.

Additionally, counterfeit Ozempic and illegally marketed versions sold online or labeled “not for human consumption” are under scrutiny for containing harmful or inactive ingredients.

Patients are advised to use only FDA-approved drugs obtained through licensed pharmacies and consult their healthcare provider about any concerns.

Adverse events can be reported to the FDA through its MedWatch program to help protect public health.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic, you may be eligible to file an Ozempic Lawsuit against the drug makers.

Contact the Ozempic Attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

The Judicial Panel on Multidistrict Litigation (JPML) recently denied a motion to expand the current Weight Loss MDL involving drugs like Ozempic to include claims related to blood clot injuries.

The plaintiffs proposed this expansion to consolidate claims of potential blood clot-related injuries allegedly linked to these drugs.

Surprisingly, defendants supported the motion, likely to avoid facing fragmented litigation nationwide.

The JPML stated that including all potential injuries associated with these widely-used weight loss drugs could make the MDL procedurally and substantively unmanageable.

This decision prevents blood clot-related claims from being added to the existing MDL.

Plaintiffs pursuing such claims now have two options:

• File a new MDL specifically focused on blood clot injuries.
• Litigate these cases individually in state or federal courts across the country.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic, you may be eligible to file an Ozempic Lawsuit against the drug makers.

Contact the Ozempic Attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

Novo Nordisk’s Ozempic is under scrutiny after two Danish studies linked the diabetes drug to an increased risk of non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition that causes vision loss due to reduced blood flow to the optic nerve.

The studies indicate that Ozempic users may be over twice as likely to develop NAION compared to patients on other diabetes drugs.

The Danish Medicines Agency has reported 19 cases of NAION among Ozempic users in Denmark and noted a sharp rise in overall cases since the drug’s market introduction in 2018.

These findings have prompted Danish regulators to urge the European Union’s drug agency to review the data.

The studies, which analyzed data from hundreds of thousands of patients in Denmark and Norway, build on earlier research from Harvard University.

While the absolute risk remains low—estimated at 0.3% to 0.5% over 20 years of use—further investigations are needed to confirm whether similar risks exist for Wegovy, Ozempic’s counterpart for obesity treatment.

Novo Nordisk maintains that the benefit-risk profile of semaglutide, Ozempic’s active ingredient, is unchanged and emphasizes patient safety as a priority.

Analysts believe the NAION risk is unlikely to significantly affect prescriptions unless Ozempic is proven unique among GLP-1 drugs in harboring this risk.

Additional studies are expected to clarify the long-term safety profile of Ozempic and related medications.

If you or a loved one have suffered from gastrointestinal issues after taking Ozempic or other GLP-1 drugs, you may be eligible to file an Ozempic Lawsuit and seek compensation.

Contact TorHoerman Law’s Ozempic Lawyers for a free consultation.

You can also use the chatbot on this page to find out if you qualify to file an Ozempic Lawsuit instantly.

The Ozempic and GLP-1 Weight Loss Drugs lawsuit involves claims that these medications have caused severe gastrointestinal side effects, including gastroparesis, nausea, and vomiting.

Plaintiffs allege that manufacturers failed to adequately warn users of these risks.

In November, 1,221 cases were filed, rising to 1,300 in December, adding 79 new claims.

This increase reflects growing awareness of the potential dangers associated with GLP-1 drugs like Ozempic.

Severe gastrointestinal complications can significantly affect quality of life, often requiring ongoing medical intervention for affected individuals.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic, you may be eligible to file an Ozempic Lawsuit against the drug makers.

Contact the Ozempic Attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

The ongoing multidistrict litigation (MDL) for GLP-1 medications, including Ozempic, Wegovy, and Mounjaro, reached a pivotal moment with the filing of a Master Complaint.

This consolidated filing outlines common allegations against Novo Nordisk and Eli Lilly, claiming the drug makers failed to adequately warn about severe gastrointestinal side effects such as gastroparesis, intestinal obstruction, and ischemic bowel.

These lawsuits involve over 1,200 claims and may grow into tens of thousands as more users link their injuries to these medications.

The Master Complaint details numerous claims, including:

• Failure to Warn
• Fraudulent Concealment
• Negligent Design
• Strict Liability for Design Defects
• Wrongful Death and Loss of Consortium

Judge Karen S. Marston, overseeing the MDL in the Eastern District of Pennsylvania, is expected to approve a Short Form Complaint soon.

This will streamline the filing process for future cases by allowing plaintiffs to adopt the Master Complaint’s allegations while adding specific details about their claims.

Next steps include addressing cross-cutting issues, such as establishing diagnostic evidence standards and preparing for “bellwether” trials, which will help evaluate how juries may respond to the evidence.

While bellwether trial outcomes won’t directly bind other cases, they could shape settlement negotiations for the growing litigation.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic, you may be eligible to file an Ozempic Lawsuit against the drug makers.

Contact the Ozempic Attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

The Ozempic Lawsuit involves claims that the diabetes medication Ozempic has caused severe gastrointestinal side effects, including gastroparesis (delayed stomach emptying), nausea, and vomiting.

Plaintiffs allege that Novo Nordisk, the drug’s manufacturer, did not adequately warn users and healthcare providers about these risks.

In October, there were 1,090 cases filed in the Ozempic lawsuit.

By November, this number increased to 1,221, with 131 additional filings.

This rise reflects heightened awareness of the drug’s potential risks and more patients coming forward with claims.

Ozempic’s side effects, particularly gastroparesis, can severely impact quality of life, causing chronic nausea and malnutrition in affected individuals.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic, you may be eligible to file an Ozempic Lawsuit against the drug makers.

Contact the Ozempic Attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

The FDA is currently reevaluating its decision to declare Eli Lilly’s obesity and diabetes drugs, Zepbound and Mounjaro, no longer in shortage, allowing compounding companies to continue producing their versions temporarily.

This development follows a lawsuit filed by the Outsourcing Facilities Association (OFA), which argued that the FDA’s decision contradicted evidence of ongoing supply issues.

The lawsuit, filed in the U.S. District Court for the Northern District of Texas, contends that the FDA’s removal of these drugs from the shortage list violated federal law by not following proper procedures, such as notifying affected companies and allowing for public comment.

In response, the FDA agreed to reassess its position and let compounders continue making the drugs while negotiations proceed.

Both parties are set to file a status report on November 21.

The case highlights ongoing supply chain challenges for popular GLP-1 medicines, like Zepbound, Mounjaro, and Novo Nordisk’s Wegovy, which have seen unprecedented demand.

While Lilly and Novo have invested heavily to increase production, shortages persist, particularly for the lower “starter” doses of Wegovy, the only formulation still listed in shortage by the FDA.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic, you may be eligible to file an Ozempic Lawsuit against the drug makers.

Contact the Ozempic Attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

The Ozempic Lawsuit involves claims that the diabetes and weight loss medication, Ozempic, has caused severe gastrointestinal issues, including gastroparesis (paralysis of the stomach), nausea, vomiting, and other serious side effects.

The lawsuit alleges that manufacturers Novo Nordisk and Eli Lilly failed to properly warn patients and healthcare providers about the risks associated with using Ozempic and other GLP-1 drugs.

In September, 869 cases were filed in the Ozempic MDL.

By October, the number of pending Ozempic Lawsuits increased significantly to 1,090, an additional 221 filings.

Ozempic and other GLP-1 weight loss drugs, while primarily used to manage blood sugar levels in individuals with type 2 diabetes, have been linked to severe digestive issues, such as gastroparesis (stomach paralysis).

This condition delays the emptying of the stomach, leading to persistent nausea, vomiting, and malnutrition.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic or other similar drugs, you may be eligible to file a lawsuit against the drug makers.

Contact the Ozempic Attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly

The ongoing multidistrict litigation (MDL) against pharmaceutical giants Novo Nordisk and Eli Lilly concerning GLP-1 drugs, including Ozempic, Wegovy, Trulicity, and Mounjaro, continues to develop as plaintiffs claim these medications have caused serious gastrointestinal injuries.

The central allegations within this litigation is that the drugs are linked to gastroparesis, a condition that paralyzes stomach muscles.

With over 900 complaints consolidated into this MDL, 85% of the cases cite gastroparesis as a primary injury.

Both sides of the litigation recently presented key scientific evidence during a “science day” session.

This event, common in large-scale pharmaceutical lawsuits, allowed attorneys and experts to share critical data about the drugs, their effects, and the underlying medical science.

Central to the plaintiffs’ argument is the claim that these medications cause gastroparesis, a serious gastrointestinal condition.

The defense, however, argued that the drugs are designed to delay gastric emptying, which is different from gastroparesis.

This distinction is a key point in their case.

Despite these technical arguments, plaintiffs’ attorneys maintain that the real-life impact of the condition on their clients will ultimately be more compelling in court.

No trial date has been set, but the science day laid important groundwork for future proceedings.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic or other GLP 1 drugs, you may be eligible to file an Ozempic Lawsuit against the drug makers.

Contact the Ozempic Attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

A recent report highlights that Ozempic and other weight loss drugs, including Wegovy, have been linked to 162 deaths in the U.S. over the past six years, according to data from the FDA Adverse Event Reporting System (FAERS).

Although these deaths haven’t been definitively proven to be caused by semaglutide, the active ingredient in these drugs, they were mentioned as factors in the fatalities.

The FAERS database has recorded 62,000 adverse reactions to these drugs, with 10,000 classified as serious.

Despite the growing concerns and reports of side effects, including gastrointestinal issues, pancreas inflammation, and gallbladder problems, the drugs continue to be widely used for weight loss.

Furthermore, in the MDL involving Ozempic and other GLP-1 medications, the U.S. District Court is evaluating whether plaintiffs must provide specific diagnostic testing to prove that they developed gastroparesis.

Specific diagnostic testing refers to a medical process where precise tests, such as gastric emptying studies, are used to confirm whether a patient has a particular condition, such as gastroparesis, by objectively measuring how well the stomach empties food into the intestines.

Additionally, the court will consider if the claims are preempted by federal law and determine whether GLP-1 drugs like Ozempic can cause the injuries in question, with decisions expected to impact the progression and potential settlement of these lawsuits.

“Preempted by federal law” means that federal regulations take precedence over state laws, preventing states from enforcing their own laws if they conflict with federal rules.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic, you may be eligible to file an Ozempic Lawsuit against the drug makers.

Contact the Ozempic Attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

The Ozempic weight loss litigation is moving forward, with Science Day set to take place soon.

Science Day is a hearing in mass tort cases, where both sides present evidence, typically including scientific studies, key documents, and expert testimonies. 

The purpose of this hearing is to provide the Court with a deeper understanding of the background of the product and the main issues of the case.

Each judge handles Science Day differently, but it is usually one of the first opportunities for the Court to fully engage with the details of the litigation.

The hearing generally lasts several hours, featuring prepared presentations and open dialogue with the Court through a question-and-answer format.

For the Ozempic litigation, Science Day offers insights for all parties involved, giving them a clearer understanding of what the legal proceedings in the coming months will look like.

Following Science Day, Judge Marston has scheduled monthly Case Management Conferences for September, October, November, and December, signaling that this litigation will likely gain momentum as the year progresses

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic, you may be eligible to file an Ozempic Lawsuit against the drug makers.

Contact the Ozempic Attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

The Ozempic Lawsuit has seen an increase in filings, rising from 346 in August to 869 in September.

Ozempic, which contains the active ingredient semaglutide, has been linked to severe gastrointestinal issues, including gastroparesis (delayed stomach emptying) and pancreatitis.

Some users have also reported experiencing thyroid tumors and other serious health complications.

These risks have led to a wave of lawsuits against the manufacturer, Novo Nordisk, with claims that the company failed to provide adequate warnings about these potential dangers.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic, you may be eligible to file an Ozempic Lawsuit against the drug makers.

Contact the Ozempic Attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

What is Gastroparesis?

Gastroparesis is a condition where the stomach empties its contents into the small intestine much slower than normal.

Symptoms include nausea, vomiting, bloating, feeling full quickly, and abdominal pain.

It can be caused by various factors, including diabetes, surgeries, infections, and certain medications.

Common Causes of Gastroparesis:

• Idiopathic: No known cause, accounts for about 50% of cases.

• Diabetes: More common in type 1 diabetes but can also occur in type 2

• Post-surgical: Following surgeries that impact the stomach or vagal nerve.

• Postinfectious: Often self-limiting but can lead to long-term issues.

How Does Ozempic Work?

Ozempic (semaglutide) is a medication primarily used to treat type 2 diabetes.

It works by mimicking a hormone called GLP-1, which helps to regulate blood sugar levels.

Ozempic increases insulin production and slows down the rate at which food leaves the stomach, which helps keep blood sugar levels stable.

This slowing effect can also lead to weight loss, as it makes you feel full longer.

Link Between Ozempic and Gastroparesis:

Ozempic slows stomach emptying to help control blood sugar, but this can worsen or trigger gastroparesis in some patients.

This side effect has led to lawsuits against Novo Nordisk for not adequately warning users.

Ozempic, a GLP-1 agonist, mimics a hormone that delays food movement through the digestive tract, causing symptoms like nausea and vomiting.

For those already prone to delayed gastric emptying, Ozempic can exacerbate their condition.

Numerous lawsuits claim that Novo Nordisk should have better communicated the risks of severe gastrointestinal side effects, including gastroparesis.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic, you may be eligible to file an Ozempic Lawsuit against the drug makers.

Contact the Ozempic Attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

The Ozempic Lawsuit focuses on claims against Novo Nordisk, the manufacturer of Ozempic, a popular medication used for the treatment of type 2 diabetes.

Plaintiffs in this litigation allege that Ozempic causes severe gastrointestinal issues, including gastroparesis, which can lead to debilitating symptoms such as nausea, vomiting, and severe abdominal pain.

These side effects have prompted numerous individuals to file lawsuits, arguing that Novo Nordisk failed to adequately warn users of these potential risks.

According to recent filings, the number of cases related to the Ozempic Lawsuit has been steadily increasing.

As of August 1st, there are 346 cases pending, the same amount as July.

The lawsuits argue that Novo Nordisk was aware, or should have been aware, of the potential for these severe side effects but failed to provide sufficient warnings to consumers and healthcare professionals.

If you or a loved one suffered from severe stomach paralysis, bowel obstruction, ileus, or other health issues after taking Ozempic, you may be eligible to file an Ozempic Lawsuit against the drug makers.

Contact the Ozempic Attorneys at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

A recent study suggests that patients taking Ozempic and Wegovy may face an elevated risk of developing non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition causing sudden vision loss.

This study, published in JAMA Ophthalmology, indicates that people with diabetes on semaglutide medications are over four times more likely to develop NAION.

Those who are overweight or obese and take these medications face a sevenfold increase in risk.

Over six years, they identified approximately 100 cases annually, noting the highest risk within the first year of medication use.

Novo Nordisk, the manufacturer of Ozempic and Wegovy, acknowledges the study but states the data does not establish causation. 

Despite the potential risk, NAION remains relatively uncommon compared to the benefits provided by these medications.

The U.S. Food and Drug Administration (FDA) includes vision changes among the possible side effects of semaglutide.

Ongoing trials by Novo Nordisk aim to explore the link between semaglutide use and diabetic retinopathy, with results expected by 2027.

Experts say patients who are taking semaglutide or considering treatment should discuss the risks and benefits with their doctors, especially those who have other known optic nerve problems such as glaucoma or preexisting visual loss.

If you or a loved one used Ozempic or other similar drugs and subsequently developed stomach paralysis, ileus, or other health problems, you may be eligible to file a lawsuit. 

Contact the Ozempic Lawyers at TorHoerman Law for a free consultation. 

You can also use the chatbot on this page to find out if you qualify to file a claim instantly.

A recent study from the University of Copenhagen highlights new concerns about GLP-1 medications, including Ozempic, Wegovy, and Mounjaro, focusing on potential bone density loss.

Published in JAMA Network Open, the study found that using these medications, without combining them with exercise, can lead to a decrease in bone mineral density (BMD) in critical areas like the hips and spine.

Ozempic, initially approved for Type 2 diabetes in 2017, has gained popularity as a weight loss drug, Its active ingredient, semaglutide, is also present in Wegovy, a higher-dose version specifically for weight loss.

Despite aggressive marketing promoting these drugs as safe and effective, GLP-1 medications have been linked to severe health risks, including gastroparesis—a condition where the stomach is paralyzed, leading to long-term gastrointestinal issues.

Thousands of lawsuits have been filed against the manufacturers for allegedly failing to warn about these risks, prioritizing profits over consumer safety.

The latest study by Dr. Simon Birk Jensen and colleagues involved a randomized clinical trial with 195 participants.

The findings revealed that participants who combined GLP-1 treatment with exercise achieved the most significant weight loss while maintaining bone health.

Those who used Victoza alone experienced a decrease in BMD.

The study showed the necessity of exercise to mitigate the decrease in bone mineral density, associated with GLP-1 medications.

If you or a loved one used Ozempic or other similar drugs and subsequently developed stomach paralysis, ileus, or other health problems, you may be eligible to file a lawsuit. 

Contact the Ozempic Lawyers at TorHoerman Law for a free consultation. 

You can also use the chatbot on this page to find out if you qualify to file a claim instantly.

Recent research highlights a significant concern for users of glucagon-like peptide-1 receptor agonists (GLP-1RAs), commonly prescribed in diabetes management.

A study, published in Gastroenterology on March 27, 2024, indicates an increased risk of aspiration pneumonia associated with GLP-1RA use during endoscopic procedures involving propofol sedation and targeting the upper gastrointestinal tract.

The retrospective cohort study analyzed health records from 80 healthcare organizations, involving adults aged 21 to 70 who underwent upper and lower endoscopies between 2018 and 2020.

Results show that GLP-1RA users, defined as individuals with a history of use exceeding six months and with at least two refills within six months prior to the procedure, experienced a higher incidence rate of aspiration pneumonia (0.83%) compared to nonusers (0.63%), corresponding to a hazard ratio of 1.33.

This risk was notably higher in procedures involving propofol sedation, specifically upper GI endoscopies, with no significant risk noted in lower GI procedures.

Dr. Ali Rezaie, Medical Director of Gastroenterology Motility at Cedars-Sinai Medical Center, emphasized the need for context, noting that while the relative risk increases by 33%, the absolute risk remains low at 0.2%.

Conversely, the American Gastroenterological Association has not found evidence to support this precaution in their latest clinical update.

Despite this, some medical centers, including Cedars-Sinai, have begun advising patients to discontinue GLP-1RA use one week prior to elective procedures.

Further guidance is expected as new recommendations are being developed, reflecting a cautious approach towards managing the increased risk of aspiration in GLP-1RA users.

If you or a loved one used Ozempic or other similar drugs and subsequently developed stomach paralysis, ileus, or other health problems, you may be eligible to file a lawsuit. 

Contact the Ozempic Lawyers at TorHoerman Law for a free consultation. 

You can also use the chatbot on this page to find out if you qualify to file a claim instantly.

A federal court in Philadelphia is handling the mass tort lawsuit filed against the manufacturers of Ozempic, Wegovy, and other weight-loss drugs.

The case raises significant concerns about the safety and regulation of these widely prescribed medications.

Ozempic and similar drugs, including Wegovy and Rybelsus (made by Novo Nordisk) and Trulicity and Mounjaro (made by Eli Lilly), are GLP-1 drugs initially approved for Type 2 diabetes treatment.

Their effectiveness in managing blood sugar levels has also led to their use in weight loss, with more than 15 million Americans reported using these drugs last month alone, with 40 times more prescriptions being written in 2023 than in 2018.

The lawsuit centers on allegations that the drug makers failed to adequately warn patients about serious gastrointestinal side effects, including gastroparesis, intestinal obstructions, and pancreatitis.

These adverse effects have been documented in recent studies and highlighted by the Food and Drug Administration (FDA).

Experts have said that this legal action contributes to an eroding public trust in both pharmaceutical companies and the FDA’s drug approval process.

A successful lawsuit could lead to increased scrutiny of GLP-1 agonists and similar drugs, potentially affecting their availability and use.

Weight-loss drugs have seen a dramatic increase in prescriptions, driven by endorsements from celebrities and widespread reports of their health benefits.

However, the ongoing litigation and associated negative publicity could dampen demand.

The outcome of this case may have far-reaching consequences for drug safety perceptions and the regulation of pharmaceuticals.

If you or a loved one used Ozempic or other similar drugs and subsequently developed stomach paralysis, ileus, or other health problems, you may be eligible to file a lawsuit. 

Contact the Ozempic Lawyers at TorHoerman Law for a free consultation. 

You can also use the chatbot on this page to find out if you qualify to file a claim instantly.

The Ozempic Lawsuit is growing, and more consumers are becoming aware of the serious side effects linked to GLP-1 medications. 

The U.S. Judicial Panel on Multidistrict Litigation (JPML) has assigned the litigation involving Ozempic, Wegovy, and Mounjaro to U.S. District Judge Karen Marston of the Eastern District of Pennsylvania.

This reassignment follows the untimely death of U.S. District Judge Gene E.K. Pratter.

The sprawling case, now under the management of Judge Marston, addresses over 10,000 personal injury claims.

The litigation focuses on severe allegations against Novo Nordisk and Eli Lilly and Co., who are accused of not providing adequate warnings regarding potential severe digestive side effects of these GLP-1 class medications.

These drugs, widely used for diabetes management and weight loss, have been linked by plaintiffs to serious conditions such as gastroparesis, severe vomiting, and bowel obstruction.

Key legal actions include finalizing the plaintiff’s fact sheet, which will detail claimants’ injuries and medical conditions, as well as their specific use of the drugs.

Defense lawyers view this stage as an opportunity to narrow the scope of the case by dismissing claims tied to counterfeit products or those lacking a proper diagnosis.

Plaintiffs’ attorneys, however, strongly oppose the premature dismissal of claims.

They are pushing for additional discovery and bellwether trials, aiming to investigate and resolve these cases thoroughly.

Judge Marston is anticipated to proceed given the high public profile of the case and its impact, considering that one in eight U.S. adults are reported to use these medications.

If you or a loved one used Ozempic or other similar drugs and subsequently developed stomach paralysis, ileus, or other health problems, you may be eligible to file a lawsuit. 

Contact the Ozempic Lawyers at TorHoerman Law for a free consultation. 

You can also use the chatbot on this page to find out if you qualify to file a claim instantly.

The Ozempic Lawsuit is growing, and more consumers are becoming aware of the serious side effects linked to GLP-1 medications. 

Growing concerns have emerged regarding the potential risks of gastroparesis associated with the use of GLP-1 receptor agonists such as Ozempic and Wegovy, commonly prescribed for obesity and diabetes management.

Gastroparesis, often referred to as stomach paralysis, is characterized by delayed gastric emptying, which can cause significant discomfort and complicate management of metabolic conditions.

Recent studies highlight the risk for gastroparesis subsequent to GLP-1 use: 

• Recent research presented at Digestive Disease Week 2024 highlights an increased occurrence of gastroparesis among patients administered GLP-1 drugs compared to those not on these medications.
• A study conducted by the University of Kansas analyzed health records from nearly 150,000 patients, revealing a 66% higher diagnosis rate of gastroparesis in those treated with GLP-1s.
• Further investigation by University Hospitals in Cleveland examined over 336,000 individuals, finding that the likelihood of developing gastroparesis escalates after six months of GLP-1 therapy.

While the overall risk remains below 1%, the data suggest a persistent increase relative to untreated individuals.

As Ozempic and Wegovy continue to be popular choices for managing diabetes and obesity, the ongoing research into their side effects like gastroparesis will remain a critical component of patient care.

Our lawyers are currently investigating cases of stomach paralysis and other serious side effects linked to these medications.

If you or a loved one used Ozempic or other similar drugs and subsequently developed stomach paralysis, ileus, or other health problems, you may be eligible to file a lawsuit. 

Contact the Ozempic Lawyers at TorHoerman Law for a free consultation. 

You can also use the chatbot on this page to find out if you qualify to file a claim instantly.  

The Ozempic multidistrict litigation (MDL) faces new challenges following the sudden and tragic death of the U.S. District Judge Gene E.K. Pratter on May 17, 2024.

Judge Pratter, aged 75, was overseeing the Ozempic MDL in the Eastern District of Pennsylvania at the time of his passing.

The loss of Judge Pratter may significantly impact the ongoing Ozempic lawsuits, which address severe gastrointestinal side effects linked to GLP-1 receptor agonists used in diabetes management and weight loss treatments.

With nearly 2% of the U.S. population prescribed these medications, the lawsuit is anticipated to escalate into a major mass tort.

These lawsuits allege that pharmaceutical companies, including Novo Nordisk, and Eli Lilly, did not sufficiently inform users about the risks associated with drugs like Ozempic, Wegovy, and Mounjaro.

As of May 1, 2024, there were 87 active lawsuits within the MDL, with potential growth to several thousand cases due to the drugs’ widespread usage.

The transition of these cases to a new presiding judge is now underway, which necessitates a comprehensive review of the existing records and a deep understanding of the related scientific and medical evidence.

This change may introduce delays in the proceedings. Moreover, an “Ozempic Science Day” scheduled for June 14, aimed at examining the scientific aspects of the litigation, now faces uncertainty.

If you or someone you know has developed gastroparesis or other health problems after taking Ozempic or other GLP-1 drugs may be eligible to file a lawsuit. 

Contact TorHoerman Law today for a free, no obligation consultation. 

For a free and instant case evaluation, use the chatbot on this page.

Ozempic, a widely used medication for weight loss, has been linked to a range of adverse effects.

A comprehensive analysis disclosed that over 9 million prescriptions for Ozempic were filled in the last quarter of 2022 alone.

However, the actual number of users might be even higher, as many people access the drug without appropriate medical supervision, often due to insurance limitations.

Our Ozempic lawyers are actively monitoring these developments, as reports of severe side effects continue to emerge.

Patients have reported conditions such as gastroparesis (stomach paralysis), gallbladder disease, and cyclic vomiting syndrome attributed to the use of Ozempic and other GLP-1 medications.

If you or someone you know has developed gastroparesis or other health problems after taking Ozempic or other GLP-1 drugs may be eligible to file a lawsuit. 

Contact TorHoerman Law today for a free, no obligation consultation. 

For a free and instant case evaluation, use the chatbot on this page.

The Ozempic lawsuit is continuing through its initial phases within the Multidistrict Litigation (MDL) framework.

On May 9, 2024, U.S. District Judge Gene Pratter, based in Philadelphia, formally designated four attorneys to serve as lead counsel for the MDL against weight loss drug manufacturers Novo Nordisk and Eli Lilly.

This lawsuit is notable not only for the claims involved but also the method employed by Judge Pratter in selecting lead counsel.

His approach combines a self-nomination by potential lead counsels and subsequent approval through a consensus among fellow plaintiffs’ attorneys, a process that could influence future complex litigations.

Judge Pratter’s selection strategy is designed to efficiently manage the vast array of cases consolidated in the Ozempic MDL, ensuring effective representation and oversight.

As the litigation progresses, the focus intensifies on the alleged safety issues associated with these drugs.

Plaintiffs contend that not all side effects, particularly severe ones like stomach paralysis, were adequately disclosed, posing significant health risks to users.

Novo Nordisk asserts that Ozempic’s safety is thoroughly documented, with all potential side effects duly reported in compliance with regulatory standards.

Individuals who have experienced serious side effects such as stomach paralysis from Ozempic, Wegovy, or other GLP-1 receptor agonists, may have grounds for a claim.

If you or someone you know has developed gastroparesis or other health problems after taking Ozempic or other GLP-1 drugs may be eligible to file a lawsuit. 

Contact TorHoerman Law today for a free, no obligation consultation. 

For a free and instant case evaluation, use the chatbot on this page.

The current Ozempic and weight loss drug litigation is in its early stages, with more lawsuits anticipated as the court defines the parameters for case filings. 

An increasing number of individuals are filing lawsuits against pharmaceutical giants Eli Lilly and Novo Nordisk.

These companies produce a class of medications known as GLP-1 agonists, which include widely used diabetes and weight loss drugs such as Ozemic, Wegovy, Rybelsus, Trulicity, and Mounjaro.

Plaintiffs claim they suffered severe digestive issues, including gallbladder removal and gastroparesis, as a result of taking these medications.

The legal claims are centralized in Philadelphia under U.S. District Judge Gene E. K. Pratter due to the shared allegations concerning the drugs’ side effects.

The majority of the lawsuits specifically target Novo Nordisk, the maker of Ozempic and Wegovy, although the number of lawsuits could potentially rise into the thousands as more individuals come forward with claims of harm.

Novo Nordisk defends the safety and efficacy of its GLP-1 medications, emphasizing the drugs’ extensive market presence of 13 years and rigorous safety evaluations in collaboration with the U.S. Food and Drug Administration (FDA).

The litigation highlights the massive popularity of GLP-1 medications in the United States, both for diabetes management and weight loss.

With forecasts suggesting 30 million users by 2030 and sales surpassing $1 billion, the stakes are high for both the pharmaceutical industry and those alleging harm from these medications.

If you or someone you know has developed gastroparesis or other health problems after taking Ozempic or other GLP-1 drugs may be eligible to file a lawsuit. 

Contact TorHoerman Law today for a free, no obligation consultation. 

For a free and instant case evaluation, use the chatbot on this page.

February 19, 2024

The Ozempic lawsuit is ongoing, with over 55 lawsuits now consolidated into the Eastern District of Pennsylvania.

The Ozempic lawsuits target severe gastrointestinal injuries reportedly caused by Ozempic and other GLP-1 receptor agonist drugs, such as Eli Lilly’s Trulicity and Mounjaro.

The lawsuits claim that Novo Nordisk and Eli Lilly, prominent manufacturers of these drugs, did not sufficiently warn patients about the risk of serious side effects, including gastroparesis (delayed stomach emptying), intestinal obstruction, and other gastrointestinal issues.

Plaintiffs argue that although the drug labels contained warnings, the pharmaceutical companies downplayed the potential severity of the gastrointestinal issues.

The MDL includes cases related to various medications, including Novo Nordisk’s Ozempic, Wegovy, Rybelsus, and Eli Lilly’s Trulicity and Mounjaro.

Recently, a federal judge in Louisiana largely denied Novo Nordisk’s motion to dismiss the lawsuit, particularly the claims concerning inadequate warnings about the risk of gastroparesis, allowing these cases to proceed.

If you or a loved one have suffered from severe gastroparesis, bowel obstruction, or other health problems after taking Ozempic or other similar drugs, you may be eligible to file an Ozempic Lawsuit.

Contact the Ozempic Lawyers at TorHoerman Law for a free consultation.

You can also use the chatbot on this page for a free case review to find out if you qualify to file an Ozempic Lawsuit instantly.

Lawsuits against Novo Nordisk, the pharmaceutical giant behind Ozempic, continue to mount as more individuals report severe side effects from the drug.

Ozempic, widely used for blood sugar regulation and weight loss, faces scrutiny over its safety after numerous patients experienced significant health issues.

An Illinois resident, aged 60, recently filed a claim stating that Ozempic caused a blocked bowel and violent vomiting, resulting in a torn esophagus and a subsequent week-long hospital stay.

This case adds to the growing number of legal actions challenging the safety of Ozempic and Wegovy, another drug produced by Novo Nordisk.

Both Ozempic and Wegovy are formulated to aid in weight management and improve pancreatic function by increasing insulin production.

However, nearly 60 plaintiffs have now alleged that these medications led to stomach paralysis or other severe conditions. The accumulation of cases has prompted the consolidation of these lawsuits in a federal court in Pennsylvania.

This centralization aims to streamline the legal process as more individuals come forward with similar allegations.

Individuals who have developed gastroparesis after taking Ozempic or other GLP-1 drugs may be eligible to file a lawsuit. 

Contact TorHoerman Law or use the chatbot on this page to find out if you qualify for the Ozempic Lawsuit.

There are a total of seven Ozempic Lawsuits pending in the newly created MDL according to the most recent JPML filings.

Multi-District Litigations (MDLs) are legal procedures in the United States designed to handle multiple related civil lawsuits that involve similar issues, facts, or defendants.

When numerous individuals or entities file lawsuits related to a common set of circumstances, such as health problems linked to Ozempic and other semaglutide medications, these cases can be consolidated into a single federal district court for pretrial proceedings.

MDLs aim to streamline the litigation process by centralizing the discovery process, reducing duplication of efforts, and ensuring consistent rulings on key legal issues.

Individuals who have developed gastroparesis after taking Ozempic or other GLP-1 drugs may be eligible to file a lawsuit. 

Contact TorHoerman Law or use the chatbot on this page to find out if you qualify for the Ozempic Lawsuit.